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Glioblastoma multiforme (GBM), a grade IV glioma, is the most common type of primary brain 
tumor, affecting about 3 out of 100,000 persons per year in the United States. GBM accounts for 
about 80% of primary malignant brain tumors, and is also the most aggressive of malignant brain 
tumors. With exhaustive treatment, survival only averages between 12 and 15 months, with a 2-
year survival rate less than 25%. New therapeutic strategies are necessary to improve the 
outcomes of this disease.  Chemotherapy with temozolomide (TMZ), a DNA alkylating agent, is 
used as a first-line of treatment for GBM. However, GBM tumors develop resistance to TMZ over 
time due to increased expression of O6-methylguanine-DNA methyltransferase (MGMT), a gene 
responsible for DNA repair.   
We previously developed cationic, amphiphilic copolymer poly(lactide-co-glycolide)-g-
polyethyleneimine (PgP) and demonstrated its utility for nucleic acid delivery.  Here, we examine 
the ability of PgP polyplexes to overcome TMZ resistance and improve therapeutic efficacy 
through combination drug and gene therapy for GBM treatment. In this study, we evaluated the 
ability of PgP to deliver siRNA targeting to MGMT (siMGMT), a gene responsible for drug 
resistance in GBM. Our results demonstrated that PgP effectively forms stable complexes with 
siRNA and protects siRNAs from heparin competition assay, serum- and ribonuclease-mediated 
degradation, confirming the potential of the polyplex for in vivo delivery.  Results from MTT assays 
showed that PgP/siRNA polyplexes exhibited minimal cytotoxicity compared to untreated cells 
when incubated with T98G human GBM cells.  We also demonstrated that PgP/siMGMT 
polyplexes mediate knockdown of MGMT protein as well as a significant ~56% and ~68% 
 
  iii 
 
knockdown of MGMT mRNA in T98G GBM cells compared to cells treated with PgP complexed 
with non-targeting siRNA (siNT) at a 60:1 and 80:1 nitrogen:phosphate (N:P) ratio, respectively.  
 Further, co-incubation of PgP/siMGMT polyplexes with TMZ enhanced therapeutic efficacy in 
T98G GBM cells compared to treatment with the polyplex or TMZ alone.  After generation of 
athymic mouse GBM model, PgP/siMGMT polyplexes were locally injected into the tumor. 
Relative to untreated injury only, PgP/siMGMT polyplexes significantly reduced MGMT mRNA 
and protein expression at 3 days post-injection. These studies demonstrate that PgP is an 
efficient non-viral delivery carrier for therapeutic siMGMT to the tumor cells and may be a 
promising platform for the combinatorial siRNA/drug therapy for GBM treatment.  In the future, 
we will study the therapeutic efficacy of the combination of PgP/siMGMT and TMZ in athymic 
mouse GBM model.    
 
  iv 
 
DEDICATION 
I would like to dedicate my work to my parents Maureen and John, and my sisters 
Phoebe and Chloe. You all inspire me every day with your youthfulness and wisdom, and 
I thank you for your never-ending support and love.  
  
 
  v 
 
ACKNOWLEDGEMENTS 
I’d like to thank my advisor, Dr. Jeoung Soo Lee, for not only giving me guidance in my research, 
but also pushing me to be the best person I can be. I would like to thank Angela Alexander-
Bryant for being the best mentor and teammate I could have asked for. I’d like to thank 
Christian Macks for helping me with every odd problem that I encountered, and thank you to 
the rest of the 4D lab members that have helped me including So Jung Gwak, Erica Beal, and 
Noah Cecil.  
I’m thankful for my committee members Dr. Lynn, Dr. Booth and Dr. Webb, and would like to 
thank the COBRE grant for funding this research.  
  
 
  vi 
 





TITLE PAGE ......................................................................................................................................... i 
ABSTRACT ......................................................................................................................................... ii 
DEDICATION .................................................................................................................................... iv 
ACKNOWLEDGEMENTS .................................................................................................................... v 
LIST OF FIGURES ............................................................................................................................ viii 
CHAPTER 
1. INTRODUCTION & BACKGROUND .............................................................................................. 1 
 
1.1. Etiology ................................................................................................................... 3 
1.2. Pathogenesis ........................................................................................................... 5 
1.3. Current Treatment .................................................................................................. 7 
 
2. BARRIERS & STRATEGIES TO OVERCOME BARRIERS ................................................................ 10 
2.1. The Blood Brain Barrier ........................................................................................ 10 
2.2. Chemotherapeutic Resistance .............................................................................. 12 
2.3. Immunotherapy .................................................................................................... 14 
2.4. Gene Therapy ....................................................................................................... 15 
2.5. GBM Treatments in Clinical Trials ......................................................................... 21 
 
3. RESEARCH AIMS ....................................................................................................................... 24 
3.1. Objectives ............................................................................................................. 24 
3.2. Multifunctional Nanotherapeutic Design ............................................................. 24 
3.3. Study Design ......................................................................................................... 25 
 
4. MATERIALS & METHODS .......................................................................................................... 27 
4.1. Materials  .............................................................................................................. 27 
4.2. Synthesis of  
poly(lactide-co-glycolide)-graft-poly(ethyleneimine) ........................................... 28 
4.3. Gel shift assay ....................................................................................................... 28 
4.4. Characterization of PgP/siMGMT ......................................................................... 29 
4.5. Cell culture ............................................................................................................ 29 
4.6. PgP-mediated MGMT silencing ............................................................................ 29 
 
  vii 
 





4.7. Cytotoxicity of PgP/siMGMT  ................................................................................ 31 
4.8. Stability of PgP/siRNA polyplexes in various  
conditions ............................................................................................................. 32 
4.9. PgP-mediated intracellular uptake of siRNAs ....................................................... 33 
4.10. Effect of MGMT knockdown on antitumor  
activity of TMZ ...................................................................................................... 29 
4.11. Generation of xenograft glioblastoma model in  
athymic mouse brain ............................................................................................ 34 
4.12. Biodistribution of DiR-loaded polyplexes after  
intratumoral injection ........................................................................................... 35 
4.13. Knockdown efficiency of PgP/siMGMT after  
intratumoral injection in athymic GBM model ..................................................... 35 
4.14. Statistical analysis ................................................................................................. 36 
 
5. RESULTS ................................................................................................................................... 37 
5.1. PgP effectively binds siRNAs ................................................................................. 37 
5.2. PgP/siMGMT polyplex characterization ............................................................... 38 
5.3. PgP delivers siRNAs into glioblastoma cells 
 in vitro .................................................................................................................. 40 
5.4. siRNA delivery displays minimal cytotoxicity in vitro ........................................... 42 
5.5. Polyplexes enter the cell through endocytosis ..................................................... 43 
5.6. PgP-mediates MGMT silencing  ............................................................................ 44 
5.7. PgP protects siRNA in physiological conditions .................................................... 45 
5.8. Effect of MGMT knockdown on TMZ cytotoxicity ................................................ 49 
5.9. Xenograft glioblastoma model in mouse brain 
was verified ........................................................................................................... 50 
5.10. DiR-loaded PgP/siNT remains in tumor for  
up to 10 days ........................................................................................................ 51 
5.11. PgP/siMGMT polyplex mediates MGMT  
knockdown in vivo ................................................................................................ 53 
 
6. DISCUSSION  ............................................................................................................................. 55 
7. CONCLUSION ............................................................................................................................ 59 
8. REFERENCES ............................................................................................................................. 61 
 
  viii 
 
LIST OF FIGURES 
 
Figure    
Page 
 
1. The CBTRUS (Central Brain Tumor Registry of the  
United States) reports distribution of histological  
subtypes of primary brain and CNS gliomas, where  
GBM makes up 54.4% (N= 92,504).1 ............................................................................. 1 
2. The CBTRUS (Central Brain Tumor Registry of the  
United States) reports distribution of average  
incidence rates of malignant primary brain and  
CNS tumors across the US.1 .......................................................................................... 4 
3. Schematic of MGMT/TMZ mechanism ....................................................................... 12 
4. PgP micelle schematic ................................................................................................. 24  
5. Agarose gel shift assay of PgP complexed with siRNA. ............................................... 37 
6. Characterization of PgP/siMGMT. .............................................................................. 38 
7. PgP delivers siRNAs into GBM cell in vitro  ................................................................. 40 
8. PgP mediates uptake of siRNAs in human  
glioblastoma................................................................................................................ 41 
9. PgP polyplexes display minimal cytotoxicity in T98G  
cells ............................................................................................................................. 42 
10. PgP polyplexes enter the cell through endocytosis. ................................................... 43 
11. PgP polyplexes mediate silencing of MGMT in T98G  
cells. ............................................................................................................................ 44 
12. Polyplexes protect siRNA from degradation in 10%  
and 50% serum conditions. ......................................................................................... 46 
13. Polyplexes protect siRNA from degradation due to  
ribonucleases .............................................................................................................. 47 
14. Polyplexes remain stable in the presence of heparin  
up to a weight ratio (WR) of 10:1 ............................................................................... 48 
15. Combination PgP/siMGMT and temozolomide 
 treatment reduces viability of T98G cells. ................................................................. 49 
16. Glioblastoma cells visualized within mouse brain tissue  
ex vivo.. ....................................................................................................................... 50 
17. GBM xenograft tumor model verified after sacrifice. ................................................ 51 
18. Local delivery of DiR-loaded PgP/siNT into tumor site. .............................................. 52 
19. DiR-loaded PgP/siNT remains in the brain tissue for at  
least 10 days ............................................................................................................... 52 
20. PgP mediates knockdown of MGMT expression in vivo.. ........................................... 53
 
  1 
 
CHAPTER 1 
 INTRODUCTION & BACKGROUND 
Each year over 25,000 new malignant brain tumors are to be diagnosed in the United 
States. With 700,000 Americans currently living with malignant brain tumors, over 170,000 are 
expected to die this year due to the cancer. With a median age of diagnosis of 64, brain tumors 
may seem to be a factor of aging, but they are also the most common cancer occurring in 
children under the age of 15. Brain tumors are the leading cause of cancer-related death in 
children between the ages of 0 and 14, and the third most common cancer-related death in 
young adults between the ages of 15 and 39.1 
There are more than 100 distinct types of primary brain and central nervous system 
tumors, the most common being meningiomas and gliomas. Meningiomas make up 36.6% of all 
primary brain tumors, but gliomas make up 74.6% of all malignant brain tumors. Gliomas arise 
from the glial, or supportive cells in the brain, 
such as astrocytes or oligodendrocytes.2 
Glioblastoma multiforme (GBM) is a high-grade 
glioma that arises from astrocytes, making it a 
type of astrocytoma. The World Health 
Organization (WHO) assigns four grades to 
astrocytomas, where glioblastomas 
make up grade IV.3,4 GBM makes up 
about 55% of all gliomas, affects about 3 
in 100,000 people, and an estimated 12,400 new cases are predicted in 2017. Glioblastomas are 
Figure 1. The CBTRUS (Central Brain Tumor Registry of the 
United States) reports distribution of histological subtypes of 
primary brain and CNS gliomas, where GBM makes up 54.4% 
(N= 92,504). 1 
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not only the most common malignant primary brain tumor, but also the most aggressive.5 
Without treatment, the survival rate for GBM is 2-3 months, and with aggressive treatment, 
survival averages between 12 and 15 months.6,2 The five year survival rate is less than 5%, due in 
part to inefficacy of treatment modalities.4 GBM is about 2 times more common in whites than 
blacks, and 1.5 times more common in men than in women.1 Clinically, patients present with 
headaches, neurological symptoms such as confusion, memory loss, seizures or personality 
change.  
The current standard of care for treating GBM includes maximal surgical resection of the 
tumor, radiation therapy and chemotherapy via temozolomide (TMZ).7 Carmustine (BCNU, 
Gliadel ™) wafers have been used as adjuvant local therapy in combination with systemic TMZ, 
but use has been limited due to observed toxicities and ambiguity of overall survival benefit.8,9 
Additionally, bevacizumab, a monoclonal antibody for the inhibition of vascular endothelial 
growth factor (VEGF), has been used since its approval as a treatment for recurrent 
glioblastomas.10 However, the 2-year survival rate after treatment remains at about only 25%.11 
GBM remains an essentially incurable disease, with recurrences taking place in most cases. High 
grade gliomas tend to be not only located in undesirable locations in the cerebral hemispheres, 
but they also have high rates of invasion into surrounding brain tissue. These factors allow for 
persistent tumor growth, and low chance of patient remission. Most adult gliomas are classified 
as diffuse gliomas, where the tumor cells diffuse into normal preexisting brain tissue. Most low 
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1.1 Etiology 
Primary brain tumors are histologically highly heterogeneous, where even between 
studies classifications and groupings of tumors often differ. The name glioblastoma 
“multiforme” is indicative of its heterogeneity. GBM is multiforme grossly, where some regions 
are necrotic, where others are hemorrhagic. On the microscopic level, regions can be found of 
pleomorphic nuclei, pseudopalisading necrosis, as well as microvasculature proliferating. GMB is 
genetically multiforme where various mutations, increased expression, or deletions cause 
tumorgenicity.5  
Histologically, glioblastoma can be diagnosed or confirmed in part due to the patterns of 
necrotic areas that occur within the tumor. The most common or symbolic of which is the 
pseudopalisading necrosis, where many small irregularly shaped necrotic foci are within dense-
packed, radially oriented glioma cells. The necrotic regions are highly hypoxic, and have shown 
to express high amounts of hypoxia-inducible factor 1a (HIF-1a), and produce increased quantity 
vascular endothelial growth factor (VEGF), which attempt to allow for inflammation and 
angiogenesis in the necrotic regions.12 The next most common necrotic pattern is described as 
having large regions of necrosis, with necrotic tumor cells and vessels. This type contains an 
intact layer of glioma cells surrounding a vessel, likely having becoming ischemic with lack of 
blood supply. This second type of large necrotic areas is found in almost all primary GBM, 
compared with only half of secondary GBM.13 
Etiologically, various risk factors have been linked to the onset of GBM, including 
smoking unfiltered cigarettes, petroleum refining work, and synthetic rubber manufacturing.14 
Other environmental risk factors include exposure to ionizing radiation, such as therapeutic, 
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exposure to vinyl chloride and to pesticides. A study done by Burch et al. showed that adults 
with brain tumors reported more use of hair dye and hair spray compared to control.15 The 
Central Brain Tumor Registry of the United States (CBTRUS) created the map shown in Figure 2 
using data from 2006 to 2010, displaying distribution of malignant primary brain tumors 
throughout the United States. Geography and environmental factors pertaining to location 
display possible correlation of malignancies with the northern regions of the United States. 1 
Zahm et al. summarized 17 studies done on the relationship between pesticide exposure 
and pediatric brain tumors. Pesticide exposure was considered a mother using household 
pesticides or insecticides, a father working in an agricultural setting, and child contact with pets. 
Nine out of 17 studies showed statistically significance between exposure and brain tumor 
development, while 5 studies showed nonsignificant correlation, and 3 studies showed no 
association.16 Factors including exposure to electromagnetic fields (EMF), formaldehyde, 
diagnostic radiation, and mobile phones have not be proven to be linked with the onset of 
GBM.2 Hereditary syndromes, such as tuberous sclerosis and neurofibromatosis, family history, 
Figure 2. The CBTRUS (Central Brain Tumor Registry of the United States) reports distribution of average 
incidence rates of malignant primary brain and CNS tumors across the US.1 
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and allergies have also been studied as risk factors. 14 Although many factors have been 
extensively studied, data is inconclusive in providing definitive measures for the prevention or 
early diagnosis of GBM. 
1.2 Pathogenesis 
Glioma development occurs due to sequential acquisition of genetic alterations, causing 
a transformation from benign to malignant tissue.17 Glioblastoma occurs in four clinical 
subtypes, but most commonly in the form of classical, or primary GBM, and proneural, or 
secondary GBM18 . Classical GBM arises de novo, and occurs in about 95% of cases, only taking 
about 3-6 months to develop. Proneural, or secondary GBM arises as a recurrence from a 
previous anaplastic or low-grade astrocytoma, usually taking 10-15 years to develop.13,2 Classical 
GBM can be classified by increased expression of mutated epidermal-growth factor receptor 
(EGFR), whereas secondary GBM has increased expression of platelet-derived growth factor 
(PDGF-A) receptor. Various genetic alterations have been identified to lead to malignant 
transformation and several will be described following.  
Classical GBM presents not only with EGFR amplification, but almost always with an 
amplification of chromosome 7 and a loss of chromosome 10. EGFR amplification is found in the 
majority of classical cases.18 It can be found in a mutated form, with a truncation due to deletion 
of exons 2-7. The mutated EGFR causes activation of the Ras-Sch-Grb2 pathway, allowing for 
proliferation and suppression of apoptosis, and enhanced tumorgenicity. Commonly, primary 
GBM presents with a phosphate and tensin homologue (PTEN) mutation and/or a p16INK4a 
deletion as well as EGFR amplification.13,4 The p16 tumor suppressor (encoded by CDKN2A) 
reduces the phosphorylation capacity of CDK4 and CDK6 cyclin-dependent kinases, therefore 
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allowing the G1 to S-phase transition in the cell cycle. Most glioblastomas with EGFR 
amplification show the p16 deletion as well.13 The phosphate and tensin homologue (PTEN) 
mutation seen in 20% of glioblastomas causes downstream activation of the P13K/Akt/mTOR 
pathway, and therefore increases cell survival and proliferation.19,20 
Proneural GBM often presents with increased expression of platelet-derived growth 
factor receptor (PDGFRA, PDGFR-α).13 Platelet-derived growth factor encourages development 
and growth of connective tissues and glia. Two cell surface receptors (PDGFR-α and PDGFR-β) 
belong to the tyrosine kinase family, and PDGFR-α has been found to be involved in tumor 
proliferation. It has been found in low and high grade astrocytomas, and therefore is thought to 
be part of the proliferation and development at all stages. PDGFR-α amplification is only found 
in 16% of glioblastoma, but in most cases of secondary GBM.13 Proneural GBM tumors are not 
only classified by increase PDGF-α, but also tumor suppressor (TP53) and retinoblastoma (RB) 
gene mutations.4 TP53 is a transcription factor that activates genes and appears to act a stress- 
induced switch that can turn on arrested cell cycle in the G1 phase, or cause apoptosis. The TP53 
mutation occurs in over 65% of secondary glioblastomas, but in less than 10% of primary GBM. 
The accumulation of the TP53 protein is more frequently observed than the actual gene 
mutation, and seen to be increasing in recurrent astrocytomas over time.13 TP53 induces the 
transcription of the MDM2 gene (mouse double minute 2), and then MDM2 complexes with 
TP53, as a negative feedback mechanism to stop its transcriptional activity. Upregulation of 
MDM2 and the TP53-MDM2 complex formation can overcome the G1 checkpoint, and 
contribute to the alternative pathways for the cell to evade the TP53 regulated control of cell 
growth.13  Previous research with adenovirus-delivered TP53 showed functional restoration of 
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the TP53 gene, leading to apoptosis in six glioma cell lines. Cellular proliferation was found to be 
inhibited in both in vitro and in vivo models, which resulted in prolonged survival in preclinical 
models.21 More recently, interferon-B (IFN-B) has been found to sensitize T98G (GBM) cells to 
TMZ, thought to be a function of also being found to induce p53 overexpression.22 The 
progression from low grade to high grade glioma is also associated with the blocked expression 
of the retinoblastoma (RB) gene, which serves to halt the cell cycle, therefore causing 
uncontrolled growth.20   
A third, hybrid subtype of GBM called mesenchymal GBM exists, most commonly is 
found in younger patients. This GBM subtype is comparable to the primary GBM subtype in that 
it arises de novo, with no previous astrocytoma precursor occurrence, and about 30% PTEN 
mutation rate.  It shares characteristics of secondary GBM, where both have greater than 30% 
rate of the TP53 mutation, and do not tend to occur in older adults.13 It also presents with low 
expression or mutations of neurofibromin (NF-1), a gene related to a hereditary skin condition. 
A fourth subtype has been classified due to its lack of similarities with the previous three 
subtypes. Neural GBM presents with no outstanding genetic amplification or mutation rates, 
differentiating itself from the others. 
1.3 Current Treatment 
Currently, the standard method of treatment for GBM begins with maximal surgical 
resection of the tumor, followed by concurrent radiation and chemotherapy.23 Because GBM 
penetrates surrounding tissues, surgical resection is unlikely to remove the tumor cells with 
comfortable margins, and further treatment methods must be used. Most often, a more 
recently approved drug, temozolomide ((8-Carbamoyl-3-methylimidazo(5, 1-d)-1, 2, 3, 5-
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tetrazin-4(3H)-one), TMZ) is administered as a chemotherapeutic agent. Temozolomide is a 
prodrug that undergoes spontaneous hydrolysis into the active metabolite 5-(3-methyl)-1-
triazen-1-yl-imidazole-4-carboximide (MTIC).  This oral alkylating agent works by promoting 
methylation most often at the O6 position on guanine, initiating a sequence of DNA mismatch-
repair events, leading to apoptosis 24,25. TMZ has between 96 and 100% bioavailability when 
delivered orally, and was approved in 1999, since being the primary choice for GBM patients.  It 
is usually administered at 75mg/m2 daily with concurrent radiotherapy (RT) for 6 weeks, 
followed by 6 more weeks of a higher dosed TMZ, at 150 mg/m2. Side effects include 
myelosuppression and nausea. The median overall survival with the described method remains 
at 14.6 months.2  
The implantable chemotherapeutic was given great attention at the time of approval, in 
1997. Carmustine (BCNU) had already been approved for systemic use, but the appeal of a local 
delivery system was justified through successful preclinical trials, and then clinical data.8 
Carmustine (BCNU) in the form of Gliadel ™ wafers are implanted into the resection cavity, to 
administer local cytotoxic drug to the GBM cells remaining after resection. BCNU is a nitrosurea, 
an alkylating drug working on the same pathway as TMZ, in which the polymeric wafers (poly 
carboxyphenoxy-propane/sebacic acid anhydride [PCPP:SA] wafers containing 3.85% BCNU) 
release BCNU for approximately 3 weeks.26 Polymeric drug delivery has been an emerging 
approach to cancer treatment, where local delivery of controlled release systems can be used to 
allow for higher drug concentrations at the tumor site, as well as reduce toxic systemic effects27. 
At the time of development of polymeric delivery systems, carmustine (BCNU) was the most 
effective form of chemotherapy for gliomas, and thus chosen for local delivery. PCPP:SA wafers 
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have shown to allow for controlled sustained release and biodegradation via surface erosion. 
Using systemic free BCNU, patient cell counts can take weeks to recover before the next dose 
can be administered. These wafers allow for drug to be delivered over multiple days or weeks, in 
comparison to free BCNU, which has a half-life of 15-30 minutes.8,27 Other drugs have been 
incorporated and tested in PCPP:SA wafers, including temozolomide, the current standard of 
treatment for GBM. TMZ impregnated wafers were even found to provide superior effects over 
oral delivery of TMZ in rodent glioma studies.27 Though the Gliadel™ wafers have been proven 
effective in preclinical in vivo studies, treatment with the wafers does not significantly improve 
patient lifespan when translating clinically. Additionally, BCNU used for local delivery of 
chemotherapy has been said to produce high interstitial drug concentration, while data has 
shown minimal penetration of the resection cavity wall, to depths of approximately 1mm.28 
BCNU wafers are not currently used in many centers due to side effects such as delayed wound 
healing, intracranial edema and infection, CSF leakage and seizure, however are still generally 
regarded as safe.2  
In addition, bevacizumab was approved for treatment of recurrent glioblastoma in 2009. 
Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth 
factor (VEGF), and is also approved for use in other human tumors, such as non-small-cell lung 
cancer.10 Progression of glioma growth has been shown to be mediated highly by tumor-
associated blood vessels, and human glioblastomas have shown to overexpress angiogenic 
growth factors, compared with normal brain tissue.29 A Phase II clinical study done, leading to 
approval,  shows that bevacizumab as a single-agent has significant antiglioma activity, as well 
as significantly effecting the vascular permeability and decreasing cerebral edema.30  
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CHAPTER 2 
BARRIERS TO TREATMENT & STRATEGIES TO OVERCOME BARRIERS 
Various systemic drugs have been used as treatments in patients with GBM, several barriers to 
providing effective treatments remain, include crossing the blood-brain barrier (BBB) and 
chemotherapeutic resistance. 
2.1 The Blood-Brain Barrier 
 It is estimated that less than 2% of small molecule drugs, and no large molecule drugs 
or genes will cross the blood-brain barrier (BBB).28  The BBB exists to regulate transport of 
essential nutrients and to protect the brain from neurotoxins. It is a cellular barrier that 
regulates ionic concentrations to allow for synaptic signaling in the brain, while also preventing 
entry of cells and large molecules via tight junctions between endothelial cells.11 Molecules can 
still cross the BBB through various mechanisms such as saturable transport, transmembrane 
diffusion, adsorptive endocytosis, and other extracellular pathways31 (Banks, 2009). Most drugs 
have been found to cross the BBB through passive diffusion or saturable transport, dependent 
on physiochemical properties of substances including charge, molecular weight and 
hydrophobicity. Lipid soluble drugs with low molecular weight are favorable for diffusion, 
whereas water soluble drugs tend to transverse using transport proteins. However, various 
efflux transport systems exist to remove unwanted substances that traverse the BBB using 
passive diffusion. A largely studied efflux pump, P-glycoprotein (ABCB1, MDR1a), has been a 
persistent challenge in drug delivery due to its efficacy in removing small molecules from the 
brain.31  A wide variety of ATP-dependent substrates are recognized by ABCB1, allowing for drug 
resistance to occur when these drugs are pumped out of cell through efflux pumps, reducing 
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cytotoxicity and drug efficacy.32 In 1994, a knockout MDR1a mouse study found that P-
glycoprotein is a major component of the BBB, after finding greatly increased administered drug 
concentrations specifically in the brain, compared with normal mice.33 Inhibitors of the action of 
ABCB1 efflux proteins have been used clinically, where they have shown to allow for increased 
drug concentrations in some cases, but have failed to reverse multidrug resistance in solid 
tumors. Two products, elacridar and tariquidar, have been approved for use as ABCB1 inhibitors, 
but complete inhibition of ABC-transport proteins at the BBB is even more difficult than in other 
tissues.11,34 
The BBB has been a consistent challenge in creating effective delivery systems for 
therapeutics. Nanotherapeutics currently in research are being designed with this challenge in 
mind, working towards creating targeted systems. However, all nanoparticles (NPs) currently 
approved are considered first generation NPs and rely on diffusion and passive targeting of 
tumor tissue via enhanced permeability and retention (EPR) effect.35,36 Fenestrated capillaries 
exist in areas of rapidly and poorly grown vessels, due to increased VEGF expression and 
angiogenesis.37,38 The leaky nature of the vasculature creates an interrupted BBB in the tumor, 
which should allow for an increase in drug or therapeutic concentration in the glioma tissue. 
However, it is possible that the leaky vasculature does not allow for therapeutically relevant 
increases in drug concentration. Séhédic et al. agrees that the EPR effect is unlikely to be 
efficient, due to the dense brain matrix and increased interstitial fluid pressure preventing 
diffusion.39 Furthermore, glioma cells tend to easily travel outside the tumor to other normal 
regions of the brain. This metastasis not only makes the glioma more difficult to treat, but also 
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reduces the quantity of drug reaching tumor cells in the intact regions of the brain with perfectly 
functioning BBB.11 
2.2 Chemotherapeutic Resistance 
Glioblastomas have been found to have either inherent resistance to chemotherapeutic 
agents, or develop resistance during treatment. Drug resistance in GBM patients has been 
attributed in part to the (O)6-methylguanine-DNA-methyltransferase (MGMT) gene. The MGMT 
gene codes for the MGMT protein that removes alkyl adducts at the O(6) position of guanine, as 
a natural repair mechanism to 
prevents apoptosis due to DNA 
crosslinking.40 Temozolomide 
promotes the addition of alkyl 
groups most frequently to the 
O(6) position of guanine, but 
also less often at the N(7)-
guanine and N(3)-adenine 
positions, in order to cause 
DNA damage and programmed 
cell death.25,41 The damage 
done from temozolomide is reversed or refuted due to upregulation of MGMT in GBM cells. Not 
only is MGMT upregulated due to the disease state, but it has been found that the TMZ 
mechanism of action causes inactivation of MGMT, which in turn leads to increased synthesis of 
MGMT protein de novo, in order to restore the natural DNA repair mechanism. TMZ, as well as 
Figure 3. Schematic of MGMT/TMZ mechanism. TMZ, a DNA alkylating 
agent, methylates DNA at the O6 position on guanine, resulting in DNA 
damage and apoptosis. MGMT, a DNA repair protein, removes alkyl 
adducts from the O6 position of guanine.  
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other alkylating agents, have therefore been found to acquire a large amount of resistance 
when used for therapy, due to the cells upregulation of MGMT and their ability to respond to 
the TMZ-caused damages by further increasing MGMT production.24 The restoration of MGMT 
by de novo synthesis occurs within hours, making the timing of TMZ dosing predictive of the 
therapeutic success.24 A continuous TMZ dosing schedule increases the exposure and depletes 
MGMT optimally, reducing the possible resistance mechanism.42 TMZ has also been found to 
induce EGFR amplification, a key agent in GBM formation, which allows for resistance 
development due to tumor progression during treatment.43 Moreover, DNA lesions induced by 
TMZ are found to activate the p53 pathway, and patients with wild-type, rather than mutant 
p53 often found in secondary GBM, are found to respond more favorably to the treatment.24  
Epigenetically, silencing of MGMT via promoter methylation has been found to be 
correlated with longer patient survival when treated with alkylating agents. Methylation of 
MGMT is only found to occur naturally in 30-60% of GBM cases.25 In a retrospective study done 
by Donson et al., the inherent silencing of the MGMT gene provides better clinical outcomes for 
pediatric patients when treated with TMZ (P=0.007), but shows to more strongly correlate with 
longer patient survival regardless of treatment (P=0.0005), suggesting it may have more to do 
with tumor progression than just the resistance to TMZ.44 Currently, attempts to overcome 
MGMT overexpression are being investigated by methods including using O6-benzylguanine as a 
pseudosubstrate for MGMT, and using RNA interference to silence the MGMT gene.45,46 
Resistance occurs further due to poly(ADP-ribose)polymerase-1 (PARP-1), a base-
excision-repair gene with activity that repairs lethal lesions (N7-guanine and N3-adenine) and 
repairs damage caused by TMZ. When PARP-1 is disrupted, cytotoxicity increases in response to 
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the methylation from alkylating drugs.41 The PARP-1 gene has been shown to have increased 
activity in GBM cells treated with TMZ, likely in response to the DNA damage. Glioma stem cells 
also appear to play a role in chemoresistance in GBM. Glioma stem cells sampled from highly 
resistant GBMs express multidrug resistance protein-1 (MDR1), and at higher levels than do 
differentiated glioma cells. These non-differentiated stem cells therefore display more 
resistance to chemotherapeutic agents, such as TMZ, furthering the proliferation of the tumor.47 
Beier et al. explains that cancer stem cells can be intrinsically resistant, where treatment doesn’t 
affect the tumor growth and recurrence is soon after treatment, or extrinsically resistance, 
where cancer stem cells survive in brain parenchyma and allow for distant recurrences.48 These 
mechanisms together can allow for highly resistant and difficult to treat glioblastomas.   
2.3 Immunotherapy 
The research community has been addressing challenges in treating glioblastoma from 
many different angles. A few critical attempts have been in immunotherapy, gene therapy and 
various drug delivery modalities. Monoclonal antibodies have been researched for the purpose 
of inhibiting oncogene activity, and providing support to the body’s immune system. Erlotinib, 
genfitinib, cetuximab, and bevacizumab have been used in phase II clinical trials to inhibit EGFR 
overactivity in high grade gliomas.30,49–51 Results have shown that as single agents, these 
biologics are not effective in treating glioblastoma with the exception of bevacizumab, showing 
significant antitumor activity compared to historical controls.30,52 Sorafenib has been researched 
in phase I clinical trials to inhibit PDGF receptor-b, with results proving safety.53,54 However, one 
phase II trial that has been completed produced only 9% of patients with 6-month progression 
free survival, rendering sorafenib to have limited efficacy in treating GBM.55 Pembrolizumab, 
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another immunotherapy, is in phase I/II clinical trials currently. It is used to inhibit the 
overexpressed programmed death ligand PD-L1 from providing protection to tumor cells in GBM 
patients, though results are not reported (NCT02530502). The increased expression of PD-L1 
inhibits recognition and elimination by T-cells, and inhibition of this PD-L1 using pembrolizumab 
may assist the immune system in fighting off cancer.  
2.4 Gene Therapy 
Gene therapy includes both the delivery of genes to be integrated into the patients’ 
cells, and the delivery genetic material to affect a patient’s gene expression. The delivery of 
genes is traditionally to replace either missing or mutant genes to correct disorders, and can be 
delivered using viral or non-viral vectors. The delivery of genetic material regards using RNA 
interference (RNAi) to affect the expression of DNA and proteins,  
2.4.1 Viral Gene Delivery 
Viral vectors have been studied and in clinical trials for years as delivery vehicles for 
genes into mammalian cells. The first clinical trial publishing gene therapy for glioma treatment 
used retrovirus-mediated HSV thymidine kinase (HSV-TK) and ganciclovir, beginning in 1992 
(NCT00001328).56,57 Certain viruses, considered neurotropic, have a tendency to interfere with 
and selectively bind with neurons and glial cells. These neurotropic viruses, such as HSV1, 
adenoviruses and paramyxoviruses have been specifically targeted as vectors for treatment of 
gliomas58–60. Various viral vector methods have been studied such as suicide gene therapy, 
which can be used to produce transcription enzymes that convert non-toxic prodrugs into lethal 
active compounds. Other virally transported gene therapy attempts include oncolytic, 
immunomodulatory and tumor suppressor gene therapy.61 Phase III clinical trials done by Rainov 
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et al. tested the effects of combining retrovirus mediated herpes simplex virus-thymidine kinase 
gene (HSV-TL) with ganciclovir (GCV) in 248 patients with newly diagnosed GBM. The HSV-TK 
gene converts prodrug GCV to its active form GCV-triphosphate, to inhibit DNA replication and 
cell division of infected proliferative cancer cells. The group found that despite safety, low 
transfection efficiency in humans remains a challenge in producing significant differences in 
treatment groups (HSV-TK/GCV combined with chemotherapy and radiation) compared to those 
treated solely with chemotherapy and radiation.62 Another clinical trial completed phase 2a in 
2010, using adenovirus-mediated HSV- thymidine kinase (AdV/TK) therapy combined with anti-
herpetic valacyclovir and radiation for the treatment of glioblastoma. Results showed that the 
treatment increased overall survival by 3.6 months compared to current standard of care.63 
Amphitropic retroviral replicating vector (RRV) Toca 511, developed by company Tocagen has 
their regimen in phase 2 clinical trials, where the Toca 511 virus infects and delivers the cytosine 
deaminase (CD) gene, and then orally taken Toca FC delivers fluorocytosine (FC) (NCT02414165). 
The CD enzyme produced allows for the FC prodrug to become an active anticancer drug (5-FU) 
and kill cancer cells, and has been concluded to be safe for intravenous administration in phase I 
trials. (NCT01985256).64 Though viral vectors have been studied extensively, they have only 
resulted in marginal increase overall survival and have yet to achieve FDA approval after 
decades of study. 
2.4.2 Non-viral Gene Delivery 
Due to the inability to translate virally delivered therapeutics to market, many 
researchers have shifted focus to non-viral vectors. Recently, much research has gone into 
studying nanoparticles for the systemic delivery of drugs or genes. Nanoparticles (NPs) have 
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been of great interest for the delivery to the brain, with aims of crossing the blood brain barrier. 
They allow for conjugation of nucleic acids, homing peptides, or targeting ligands. Major types 
of nanoparticles used for delivery in glioblastoma include polymeric nanoparticles, liposomes 
and lipid nanoparticles. 
Polymeric nanoparticles 
Polymeric nanoparticles are widely studied due to their multifunctionality, and their 
ability to improve solubility, stability and biodistribution of therapeutics they carry.65 They tend 
to be safer and more predictable than viral vectors. Aside from the array of naturally available 
polymers, there are endless possibilities in the field of synthetic polymers. The ability to create a 
nanoparticle to fit the biodegradation and drug-release profile needed for specific applications is 
appealing for drug and gene delivery alike. For delivery to brain tumors, polymeric NPs have 
potential capability to transport substances across the BBB. A few main types of polymeric NPs 
used for targeting glioblastoma include dendrimers, poly(β-amino ester) (PBAE) and 
polyethyleneimine (PEI).  
Dendrimers are highly branched synthetic polymers that have been used for the delivery 
of nucleic acids, specifically siRNAs. They also have the ability to incorporate drug delivery or 
imaging agents for additional therapeutic benefit. Poly(amidoamine) (PAMAM) dendrimers have 
been of interest because they can conjugate with siRNAs and targeting ligands such as folic acid 
for increased delivery specificity, and have been found to cross the BBB. A study by Waite et al. 
conjugated cyclic RGD (arginine-glycine-aspartic acid) peptide to PAMAM dendrimers, as a 
targeting moiety to cellular integrins. They then conjugated siRNAs to the complex and delivered 
to U87 glioma cell spheroids, with findings that their delivery system was able to penetrate 
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malignant spheroids and efficiently produce gene silencing.66 One critical limitation of PAMAM 
dendrimers for clinical translation is cytotoxicity due to their high positive surface charge.  
Studies have shown that PAMAM dendrimers exhibit neurotoxicity by inducing autophagy in 
glioma cells resulting in cell death.67  Strategies to mitigate this effect include reducing the 
surface charge through acetylation or functionalization using PEG. 
One group used a poly(β-amino ester) nanoparticle conjugated with DNA coding for the 
herpes simplex virus-thymidine kinase gene (HSV-tk), and ganciclovir (GCV) for therapy in glioma 
cell lines. They found that the cell lines (9L and F98) in vitro had 100% cytotoxicity compared the 
cells transfected with green fluorescent protein (GFP), an innocuous gene, and also treated with 
GCV. When delivered in vivo, they found that glioma-bearing rats had a significant survival 
benefit over control rats.68 Another group used the biodegradable PBAEs conjugated to DNA and 
achieved over 60% transfection in human brain tumor initiating cells (BTICs) in nude mice, and 
significant specificity for transfection in tumor tissue over normal brain tissue.  PBAEs show 
promise as a non-viral vector for genes in brain tumors, with lower immunogenicity and higher 
transfection efficiency.69 
Polyethyleneimine (PEI) is another commonly used synthetic nanoparticle that can 
effectively complex with nucleic acids, such as siRNA and DNA. PEI is a cationic polymer that can 
be modified with hydrophobic polymers or targeting ligands for combination drug delivery or 
targeted delivery, respectively.  PEI can easily penetrate the cellular membrane, and escape the 
endosome using proton buffering. Additionally, to reduce the cytotoxic effect of PEI and enable 
attachment of targeting ligands, poly(ethylene glycol) (PEG) conjugation is commonly applied to 
PEI.  RGD ligands and PEG have been conjugated to PEI for the delivery of plasmid DNA. Zhan et 
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al. found that this complex allowed for efficient gene transfection in U87 glioma cells in vitro 
and in vivo.70 
Cationic liposomes and lipid nanoparticles 
Liposomes have been studied extensively as a non-viral vector for the use of drug and 
gene delivery. Cationic lipids tend to electrostatically complex with DNA to form positively 
charged lipoplexes.71,72 Though gene delivery via liposomes has been accepted as safe, 
liposomes have not proven highly effective for gene transfection in humans. However, 
liposomes have the ability to carry hydrophobic or hydrophilic molecules within their vesicular 
structure, making them good vehicles for drug delivery. In delivery to tumors, it has been found 
that cationic liposomes accumulate in tumor tissues due to their positive charge. To deliver 
across the BBB to brain tumors, one group used focused ultrasound to deliver doxorubicin 
loaded cationic liposomes (DOX-CLs), and then allowed DOX-CL to target C6 glioma tissue in 
vivo. They found that the delivery system increased animal survival time and decreased 
progression of glioma growth, compared with free DOX.73 A study by Calcagno et al. developed a 
cationic liposome (scL-TMZ) for the delivery of TMZ to glioblastoma cells (U87R). They found 
that the liposome increased the sensitivity of resistant cells to TMZ treatment compared to 
when treated with free TMZ.74 The only synthetic nanomedicine to reach clinical trials for 
systemic delivery to data are cationic liposomes.61  
Solid lipid nanoparticles have been in laboratories since the 1990’s, and are studied in 
delivery to the brain in part due to their hydrophobic, low molecular weight characteristics, 
making them favorable for transport across the BBB.11 Lipid NPs have advantages over other 
delivery systems, such as good biocompatibility, controlled drug release and minimal 
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cytotoxicity. They also have the ability to deliver otherwise highly insoluble lipophilic drugs 
across the BBB.75 Nanostructured lipid carriers (NLCs) are composed of solid and liquid lipids, 
allowing for greater drug loading due to an imperfect crystal structure. A study by Chen et al. 
loaded TMZ and pGFP into NLCs (made from soya lethicin, DDAB and tween 80), to determine 
feasibility in delivering drug and gene through the mouse tail-vein to human glioma tumors 
(formed subcutaneously with U87 cells). They found significant increase in gene transfection 
compared to positive control Lipofectamine 2000, and significantly increased cytotoxic effect 
compared with free TMZ.76 One group investigated the ability of polymeric NPs, solid lipid NPs 
and nanostructured lipid carriers to deliver TMZ to glioblastoma tumors. They developed each 
nanoparticle to be loaded with TMZ and evaluated the anti-tumor activity in vitro and in vivo, 
and found that the nanostructured lipid carriers displayed the most significant glioma growth 
inhibition.75 
2.4.3 RNA interference 
RNA interference (RNAi) has become the gold standard for the silencing of genes since 
its discovery in 1998.77  RNAi can be achieved by using plasmid DNA (pDNA), small hairpin RNA 
(shRNA) or short interfering RNA (siRNA). MicroRNAs (miRNAs) are another interference method 
used, similar to siRNA in length and non-coding nature, but lacking the limited specificity to one 
mRNA. Most commonly focused on for gene silencing is siRNA, due to its specificity and proven 
safety and efficacy.78 Interference occurs when the antisense siRNA will bind to a target mRNA 
to induce nucleolytic degradation of a specific gene, and prevent translation of a desired 
protein.  In cancer, siRNAs have been found to be useful in silencing proliferative genes, or 
oncogenes, that allow for uncontrolled growth of tumors, as well as showing promise in 
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sensitizing cancer cell to chemotherapeutics.78 Initially, local delivery of siRNAs to the tumor was 
relied on for therapeutic effect, however research has progressed in creating delivery systems to 
protect the siRNA stability from degradation by nucleases in the body using carriers such as gold 
nanoparticles, polymeric micelles and liposomes.77 Specificity and efficiency of siRNA have been 
proven in vitro, in vivo and through clinical trials, but not without unwanted effects such as 
nonspecific inflammation and challenges such as siRNA instability and producing controlled 
siRNA release from the delivery vessel.77 Yoo et al. has researched an iron oxide nanoparticle 
conjugated chlorotoxin peptide (CTX) for targeting GBM cells (T98G) and to siMGMT for 
silencing MGMT. They found that their nanoparticle increased sensitivity to TMZ and 
cytotoxicity in vitro and in vivo, but were unable to distinguish if this effect was due to CTX or 
the MGMT silencing.79 Wang et al. published work delivering siRNAs to silence EGFR and β-
catenin in GBM cells (U-87 MG), where they found that cell proliferation was reduced when 
treated with siRNAs targeting  β-catenin and β-catenin + EGFR, but not EGFR alone.52 Clinical 
trials using siRNAs are few, with only a handful attempted for the treatment of tumors. Clinical 
trials administering siRNAs for the direct silencing of genes for GBM treatment have yet to be 
attempted.80,81 The use of RNA interference can be very valuable in reducing the expression of 
genes and proteins in certain cells, rather than introducing new or improved genes into the 
genome.  
2.5 GBM Treatments in Clinical Trials 
Previously discussed therapies in clinical trials, as well as additional treatments for 
glioblastoma currently in clinical trials are displayed in Table 1.  Most treatments in clinical trials 
currently are virally delivered gene therapies, combined with cytotoxic drugs. However, 
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therapies include a vaccine, neural stem cell injections, and an MGMT pseudosubstrate. A 
survivin peptide vaccine (SurVaxM) treatment is currently in clinical trials with attempts to treat 
gliomas by eliciting an immune response to the overexpressed survivin protein in GBM cells. In 
phase 2 trials, SurVaxM has been used in combination with TMZ, Sargramostim, and Montanide 
ISA 51 VG, in order to kill cancer cells, restore blood cells suppressed due to the therapy, and as 
an adjuvant to human vaccine, respectively. (NCT01250470)82,83 In vivo studies show that siRNA 
knockdown of survivin induces apoptosis in GBM tumors and significantly inhibits glioma 
growth.84  
A phase I clinical trial implanted neural stem cells (HB1.F3) expressing E. coli cytosine 
deaminase (CD) into the resection cavity of high grade glioma tumors. Oral 5-fluorocytosine (5-
FC) was given, with the intent of the expressed CD enzyme to convert 5-FC to the lethal 
compound 5-FU. This first in man study concluded safety and feasibility to target brain tumors, 
as well as produce a local cytotoxic effect (NCT01172964).85 Phase II clinical trials are currently 
recruiting recurrent GBM patients for the study of SGT-53, a cationic liposome encapsulating 
wild-type p53 tumor suppressor gene in a plasmid backbone, in hopes that the delivery of 
normal p53 gene in combination with TMZ will provide longer overall survival (NCT02340156). 
SGT-53 has shown promise in mice, where sensitivity to TMZ was shown to be enhanced with 
treatment.86 O6-benzylguanine (O6-BG) was developed as a substrate inhibitor of MGMT, 
working by binding to MGMT and diminishing the enzyme activity. O6-BG has been and is still in 
clinical trials, in combination with alkylating agents TMZ and BCNU, and has shown thus far to 
increase sensitivity of the tumors to the alkylating agents.45 A phase II clinical trial has been 
completed using O6-benzylguanine in combination with temozolomide in pediatric patients with 
 
  23 
 
high-grade gliomas, and it was concluded that the combination did not achieve the target 
therapeutic response rate.45,24 However, another phase II clinical trial of TMZ plus O-6BG in 
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Table 1. Current state of clinical trials for the treatment of glioblastoma multiforme. 
 





The current treatment options for glioblastoma do not effectively improve the disease, and 
great improvement is needed to extend patient lifespan. The overall goal of this research is to 
develop a multifunctional nanotherapeutic for the treatment of malignant glioblastoma. It is 
hypothesized that combinatorial delivery of temozolomide and siRNA targeting MGMT will 
sensitize tumor cells to TMZ, a DNA alkylating agent, due to the knockdown of MGMT. This 
study will focus on nucleic acid delivery for the future combination treatment with TMZ. 
3.2 Multifunctional Nanotherapeutic Design 
The polymeric micelle PgP, or poly(lactide-co-glycolide) -graft-polyethyleneimine, is a novel 
polymeric system developed by our lab, with the potential to deliver nucleic acids and drugs. 
The cationic, amphiphilic copolymer assembles spontaneously into micelles in an aqueous 
environment.  As represented in Figure 4, the hydrophobic PLGA constructs the core, and the 
positively charged polyethyleneimine (PEI) makes up the shell of the micelle. PgP is designed to 
Figure 4. PgP micelle schematic. The micelle formation of poly(lactide-co-glycolide)-graft-poly(ethylenimine), PgP. 
Hydrophobic PLGA orients into the core and the hydrophilic PEI orients to the shell of the micelle formation. The cationic 
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be complexed with negatively changed nucleic acids to form a polyplex held together with 
strong electrostatic interaction between the nucleic acids (such as siRNA) and the PEI shell. The 
hydrophobic core allows hydrophobic or lipophilic drugs to be loaded within for delivery. The 
approximately 200nm polyplex is strategically between the sizes of kidney and liver excretion, 
designed to allow the polyplex to avoid clearance and stay in circulation when administered 
intravenously. When the polyplex enters circulation, it can be targeted to cancerous tumors via 
the enhanced permeability and retention (EPR) effect, as described previously. Once the 
polyplex makes its way into the tumor cell, it can be taken up into the cell via endocytosis, and 
escapes by means of the proton sponge effect. Due to the cationic nature of the polyplex, the 
endosome will swell in attempt to maintain homeostasis, and eventually rupture, allowing the 
contents to release into the cytosol, and siRNA to escape.  
3.3 Study Design 
Determining efficacy of this polyplex includes determining the stability of the PgP when 
conjugated with siMGMT. Once the stability is determined in vitro, the cytotoxicity of the 
polyplex in human glioblastoma (T98G) cells will be assessed.  The efficacy of siRNA delivery, as 
well as the reduction in gene expression and protein production will be evaluated in vitro. The 
stability of the polyplex will be evaluated by presenting the polyplexes to various physiological-
like conditions in vitro, such as serum and ribonucleases.  Given the polyplex is proven stable in 
physiological conditions, the cytotoxicity is minimal, and the polyplex proves effective in siRNA 
delivery, the delivery system will be introduced to mice, for in vivo studies of efficacy. In vivo 
studies first involve producing a xenograft glioblastoma model. This will involve introducing 
T98G cells, as studied in vitro, into the brains of nude mice. Determination of the tumor growth 
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can be made with analysis of the brain tissue ex vivo, on the macroscopic and microscopic levels. 
Confirmation of tumor cell growth within the mice can allow this project to move forward to 
studies of the polyplex biodistribution and therapeutic efficacy.  Therapeutic efficacy of 
PgP/siMGMT will be evaluated in mice by injecting polyplex to the tumor site, then removing 
tumor tissue for protein and RNA extraction. Comparing untreated control tumor tissue with 
treated tissue will allow knockdown efficiency in vivo to be analyzed. Future studies can include 
assessing the antitumor effect of MGMT knockdown when combined with TMZ. 
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CHAPTER 4 
MATERIALS & METHODS 
4.1 Materials 
Poly(lactide-co-glycolide) (PLGA, 4KDa 50:50) was obtained from Durect Corporation, Pelham, 
AL. with a carboxylic end group and 25 kDa branched polyethyleneimine (bPEI) was purchased 
from Sigma-Aldrich, St. Louis, MO. All siRNAs were purchased from GE Healthcare Dharmacon 
(Lafayette, CO).  siRNA targeting MGMT (O6-methylguanine-DNA methyltransferase, NCBI 
Reference Sequence: NM_002412.4, siMGMT) was custom-synthesized.  siGENOME non-
targeting siRNA #5 (siNT) was also purchased and used as a negative control siRNA.  Additionally, 
siNT with a fluorescein label (FI-siNT) at the 3’ end of the anti-sense strand was synthesized and 
used in fluorescence experiments. The T98G cell line was obtained from ATCC in Manassas, VA.  
LysoTracker™ Blue DND-22 and Mouse monoclonal anti-MGMT antibody (clone MT3.1), Halt™ 
Protease & Phosphatase Inhibitor Cocktail, Pierce BCA protein assay kit, SuperSignal™ West Pico 
Chemiluminescent Substrate, and the cDNA Reserve Transcription Kit were obtained by Fisher 
Scientific. Mouse monoclonal anti-β-actin antibody (1:5,000) was obtained from Santa Cruz 
Biotechnology, Dallas, TX. Goat anti-mouse secondary antibody was obtained from Southern 
Biotechnology, Birmingham, AL. Immun-Blot® PVDF membranes were obtained from Bio-Rad 
Laboratories, Hercules, CA. Phenylmethanesulfonyl fluoride and Thiazolyl blue Tetrazolium 
Bromide (TBTB) were obtained from Sigma-Aldrich. Taqman® Gene Expression Assays Thermo 
Fisher Scientific, Waltham, MA. Nude athymic mice (Foxn1nu) were obtained from Envigo. 
Buprenorphine was obtained from Hospira, Inc. Hamilton syringes were obtained from Hamilton 
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Company, Reno, NV. Nucleospin RNA/Protein kit was obtained from Machery-Nagel, Bethehem, 
PA. 
4.2 Synthesis of poly(lactide-co-glycolide)-graft-poly(ethyleneimine) 
The cationic, amphiphilic copolymer poly(lactide-co-glycolide)-g-polyethyleneimine (PgP) was 
synthesized as previously described 89 using 4 kDa poly(lactide-co-glycolide) (PLGA, 50:50) with a 
carboxylic end group and 25 kDa branched polyethylenimine (bPEI). PgP was purified using a 
dialysis membrane with molecular weight cut-off (MWCO) of 50,000 Da. PgP was then 
centrifuged at 5,000 rpm for 10 minutes in order to remove excess PLGA precipitate, and 
lyophilized for storage.89  
4.3 Gel shift assay 
In order to determine the optimal N/P (amine: phosphate) ratio necessary for complete binding 
of the PgP and free siRNA complex, a gel shift assay was performed. A 2% agarose gel was 
prepared with a 12-well comb. PgP was complexed with siRNA in deionized water at various N/P 
ratios ranging from 0 to 25 and incubated for 30 minutes at 37°C. Loading dye was added to the 
samples and each was loaded into the gel, then samples were electrophoresed at 100V for 25 
minutes. It was stained with 0.2% ethidium bromide in water for 10 minutes and then rinsed 
with water for 15 minutes on a shaker. The ChemiDoc-It2™ system was used to image the gel 
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4.4 Characterization of PgP/siMGMT 
To evaluate the particle size and surface charge of polyplexes, PgP was complexed with siMGMT 
(20 µg) at N/P ratio of 30:1 and 60:1. The N:P ratios were identified from gel shift assay. The 
polyplex was measured in using a Zetasizer (Malvern Zetasizer ZS DLS-Zeta) instrument that 
measured particle size, polydispersity index (PDI), and surface charge (zeta potential). 
4.5 Cell culture 
The human glioblastoma cell line T98G was cultured in specified growth media supplemented 
(EMEM) with 10% fetal bovine serum (FBS) and 1% antibiotic (100IU/ml penicillin/100µg/ml 
streptomycin), and grown in an incubator at 37°C with 5% CO2. 
4.6 PgP-mediated MGMT silencing 
The efficiency of siMGMT transfection and MGMT silencing was quantified in T98G cells. 
Polyplexes were formed by complexing PgP with siMGMT (100 nM) at N/P ratios of 30:1, 60:1, 
and 80:1 in sterile deionized water at 37°C for 30 min.  siMGMT complexed with Lipofectamine 
2000 was used as a positive control.  Additionally, at each N/P ratio, siNT was complexed with 
PgP as a negative control for comparison of each treatment.  T98G cells seeded at 1x105 cells 
per well and cultured in 12-well plates were washed three times with media and incubated with 
PgP polyplexes for 24 hours in media containing 10% FBS, after which, cells were again washed 
three times with media and incubated with complete media containing 10% FBS for another 24 
hours.  48 hours post-transfection, protein or RNA was extracted from the cells for western blot 
or real-time PCR analyses, respectively, as described in the following sections. 
 
 
  30 
 
To analyze the knockdown of MGMT on the protein level, western blot was performed. 
48 hours post-transfection, cells were washed with 1X cold PBS and lysed with ice cold RIPA 
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, and 1% NP-
40)) containing protease inhibitor, phenylmethanesulfonyl fluoride and Halt™ Protease & 
Phosphatase Inhibitor Cocktail. Total protein concentration was determined using the Pierce 
BCA protein assay kit via the manufacturer’s instructions.  3 µg of protein lysates were resolved 
by SDS-PAGE using polyacrylamide gels and transferred onto Immun-Blot® PVDF membranes. 
PVDF (polyvinylidene fluoride) membranes were blocked for 1 hour in Tris-HCl-buffered saline 
containing 0.1% Tween-20 (TBS-T) and 5% milk.  Following blocking, membranes were incubated 
with mouse monoclonal anti-MGMT antibody (1:500) or mouse monoclonal anti-β-actin 
antibody (1:5,000) overnight at 4°C then washed four times with TBS-T and incubated in 
horseradish peroxidase-conjugated goat anti-mouse secondary antibody (1:2,000 or 1:10,000) 
for one hour. SuperSignal™ West Pico Chemiluminescent Substrate (Fisher Scientific) was used 
to detect immunoreactive bands which were subsequently imaged using the ChemiDoc-It2™ 
Imager. 
To analyze MGMT knockdown on the mRNA level, RT-PCR was used. After 48 hours 
transfection, total RNA was extracted from cells using the RNeasy® Plus Mini Kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions. The concentration and purity of 
isolated RNA was determined using the Biotek plate reader and Take3 Micro-Volume Plate.  
Isolated RNA (100 ng) was reverse-transcribed using the High-Capacity cDNA Reserve 
Transcription Kit with MultiScribe® Reverse Transcriptase (RT) and RT Random Primers.  Real-
time PCR was performed using a Rotor Gene Q thermal cycler (Qiagen) with predesigned 
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Taqman® Gene Expression Assays for MGMT (Hs01037698_m1), and the endogenous control, 
18S (4319413E), combined with Taqman® Gene Expression Mastermix according to the 
manufacturer’s instructions.  The threshold cycle (CT), the cycle number at which the 
fluorescence generated within the reaction crosses the threshold line, was determined.  Relative 
mRNA expression of MGMT was calculated using the 2-
ΔΔ
CT method.  Minus RT reactions were 
also performed to ensure that there was no significant genomic DNA contamination. 
4.7 Cytotoxicty of PgP/siMGMT 
To evaluate if the polyplex caused toxicity to the cells, a cytotoxicity study was performed. T98G 
cells (1X105 cells/well) were cultured in 24-well plates and allowed to attach overnight. PgP 
polyplexes were formed using siNT (100nM) at N/P ratios of 30:1, 60:1 and 80:1, incubated at 
37°C for 30 minutes. Controls consisted of untreated cells, siNT alone, and 
Lipofectamine2000/siNT. Polyplexes were incubated with T98G cells for 24 hours in media 
containing 10% FBS, and then washed three times with media and incubated for an additional 
24 hours. At 48 hours post-transfection, an MTT assay was performed to determine cytotoxicity. 
Cells were incubated with 120 µL/well of Thiazolyl blue Tetrazolium Bromide (TBTB) dissolved in 
PBS at 2 mg/ml, added to 500µL media. After a 4 hour incubation at 37C, the media containing 
TBTB was aspirated and 500µL DMSO was added to each well to dissolve formazan crystals. 
Wells were thoroughly mixed using micropipette and 100µL from each sample was removed and 
transferred into a 96-well plate. The Biotek Synergy plate reader (Winooski, VT) was used to 
measure absorbance of wavelength of 570 nm in order to determine concentrations of 
formazan in each well. Samples were normalized using untreated cells, and cell viability was 
determined using following equation: Cell viability (%) = (OD570(sample)/OD570(control)) x 100%. 
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4.8 Stability of PgP/siRNA polyplexes in various conditions 
4.8.1 Heparin competition assay 
To determine the stability of the PgP/siRNA polyplex, polyanion heparin was introduced to the 
polyplex. First PgP/siRNA polyplexes were formed at an N/P ratio of 60:1 and incubated for 30 
minutes at 37°C. Then heparin was added to the samples at various weight ratios (heparin: 
siRNA) and incubated for 30 additional minutes. Control groups of siRNA alone and PgP/siRNA 
without heparin were included. Weight ratios included 1, 2, 5, 10, 20, 50 and 100. Conditions 
described previously were used to run the gel with 20 uL of each sample was loaded.  
4.8.2 Serum and RNase protection assay 
 The stability of the polyplexes in the presence of serum and RNase were tested and compared 
to the stability of the polyplex in water. PgP/siRNA was also compared to negative control of 
siRNA alone, and known transfection reagents PEI and Lipofectamine® 2000 (LIPO). PgP/siRNA 
was complexed at N/P 60:1 in water for 30 minutes at 37°C; PEI/siRNA was complexed at N/P 
5:1 in water and incubated for 30 minutes; LIPO/siRNA was complexed in Opti-MEM at 
manufacturer suggested N/P; and naked siRNA was prepared in water. 
Samples were next exposed to 10% serum, 50% serum, or 0.1 µg RNAse A conditions and 
incubated 1 hour at 37°C. After incubation, 10% SDS was used to dissociate the siRNA from 
complexes, and samples were immediately run through gel electrophoresis using above 
described conditions. Each sample was compared to a respective control where the serum or 
RNAse conditions were replaced with a 30-minute incubation in water.  The samples were 
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examined by gel electrophoresis using a 2% agarose gel stained with ethidium bromide and 
imaged with the ChemiDoc-It2™ Imager. 
4.9 PgP-mediated intracellular uptake of siRNAs 
Transfection efficiency using PgP as a delivery system was tested by first transfecting T98G cells 
with fluorescently labeled siRNA (FI-siNT) and observing using fluorescent microscopy. T98G 
cells were seeded in 12-well plates at 1X105 cells per well and allowed to attach overnight. PgP 
was complexed with FI-siNT (100 nM), a fluorescein non-targeting siRNA, at N/P ratios of 30:1, 
60:1, and 80:1 and incubated for 30 minutes at 37°C. FI-siNT alone was used as a negative 
control and FI-siNT complexed with PEI (5:1) or Lipofectamine 2000 were used as positive 
controls. Media (EMEM + 10% FBS) was added to each sample and then 1 mL was added to each 
well. Each well contained 2 µg siRNA. After 6 hours, cells were washed three times with 1X 
phosphate buffered saline (PBS) and transfection efficiency was evaluated based on density and 
brightness of cell fluorescence using confocal microscope.  To examine the uptake mechanism of 
polyplexes, cells were stained with LysoTracker™ Blue DND-22 according to the manufacturer’s 
instructions prior to imaging.  
For quantitative analysis, flow cytometry via the Guava Easycyte ™ (Millipore, Darmstadt, 
Germany) was used to determine transfection efficiency. Cells were trypsinized and removed 
from well plates, and each sample was run through the flowcytometer. Cell populations were 
gated according to fluorescence of untreated cells. A heparin wash was used to ensure that 
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4.10 Effect of MGMT knockdown on antitumor activity of TMZ 
To evaluate the effect of MGMT knockdown on the cytotoxicity of TMZ, combination treatment 
was performed. T98G cells were plated at 1X105 cells per well in 24-well plates and allowed to 
attach overnight. PgP/siMGMT polyplexes were made at N/P ratio 60:1 and incubated for 30 
minutes. Polyplexes were added to the cells, immediately followed by TMZ addition at 
concentrations of 500 µM (half the IC50 value) and 1000 µM (IC50).  MTT assay was performed 
72 hours after transfection. Untreated cells were used as a control. Free TMZ, PgP/siNT with 
TMZ, and PgP/siNT or PgP/siMGMT without TMZ were used for comparison  
4.11 Generation of xenograft glioblastoma model in athymic mouse brain 
All animal procedures were conducted according to NIH guidelines for the care and use of 
laboratory animals (NIH publication No. 86-23, revised 1996) and approved by the Clemson 
University Animal Research Committee (animal protocol number AUP 2016-080). Eight week-old 
nude female athymic mice were used to create a GBM brain tumor model. Mice were 
anesthetized using isofluorane gas and were arranged into a stereotactic frame. Buprenorphine 
(0.1 mg/kg) was injected subcutaneously for pain before incision. An incision was made along 
the sagittal plane on the scalp, the bregma was located and the point 1.5 mm to the right was 
marked. A 26-guage Hamilton syringe containing 4µL of T98G cells, a total of 150,000 cells, was 
assembled into the stereotactic frame and inserted 3 mm deep into the brain. The cells were 
injected at a controlled flow rate of 1 mL/min and then the syringe was allowed to remain in the 
injection site for 5 minutes before removal. The syringe was slowly removed and sterile bone 
wax sealed the hole in the skull and the incision site was sutured.  
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4.12 Biodistribution of DiR-loaded polyplexes after intratumoral injection  
We first evaluated the biodistribution of polyplexes to determine whether polyplexes remain in 
the tumor or diffuse out after intratumoral injection. To visualize the polyplexes, DiR was loaded 
into PgP using solvent evaporation method. Two weeks post-injection of tumor cells, mice were 
treated with with DiR-loaded polyplexes (DiR-PgP/siNT) for biodistribution analysis. Using the 
procedure previously described, mice were anesthetized, arranged in stereotactic frame, and 
injected with DiR-PgP/siNT, containing 2µg siRNA and 4µL volume. The injections were 
performed at the same original injection site (1.5 mm right of bregma, 3mm deep) at a flow rate 
of 1µL/min.  Mice were imaged at 1 hr, 3 hr, 6 hr, 24 hr, and then every 48 hours for 10 days. 
Live animals were anesthetized using isoflurane and placed into the IVIS Luminar XR in vivo 
imaging system (Caliper Life Science). An excitation wavelength of 745nm and emission of 
790nm was used to image the DiR loaded polyplex, to analyze the biodistribution of polyplexes. 
At day 10, mice were euthanized and organs were extracted for ex vivo analysis of the complex 
retention in tissues. 
4.13 Knockdown efficiency of PgP/siMGMT after intratumoral injection in athymic GBM model 
For knockdown efficiency analysis, mice were treated with siNT or siMGMT (2 µg, 4 µL volume) 
complexed with PgP, four weeks post-injection of tumor cells. Using the procedure previously 
described, mice were anesthetized, arranged in stereotactic frame, and injected with PgP/siNT 
or PgP/siMGMT, containing 2µg siRNA and 4µL volume. The injections were performed at the 
same original injection site (1.5 mm right of bregma, 3mm deep) at a flow rate of 1µL/min. Mice 
were euthanized 72 hours post-treatment and the brain was excised and preserved in RNAlater. 
A 1mm x 1mm x 2mm sized tissue sample was taken from each brain at the same location, in 
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order to remove tumor tissue. RNA and protein was extracted using Nucleospin RNA/Protein kit 
according to the manufacturer’s instructions. Following extraction, the RNA purity and 
concentration was quantified using the Take3 plate reading system. The protein concentration 
was quantified by performing BCA assay, and protein was analyzed using western blot, using the 
methods previously described. The MGMT mRNA expression was evaluated by performing 
reverse transcription and then RT-PCR, as described previously.  
4.14 Statistical Analysis 
Quantitative data were presented as mean ± SEM.  Statistical analysis was performed using 
either Student’s t-test or one-way ANOVA (Bonferroni’s Multiple Comparison Test). A value of 
P<0.05 was considered statistically significant.  All statistical analyses were examined using 








5.1 PgP effectively binds siRNAs 
The amphiphilic, cationic micelle PgP was designed to self-assemble with a hydrophobic PLGA 
core, and a positively charged PEI shell, for the formation of a polyplex when bound with nucleic 
acids. This gel shift assay was performed in order to determine the effective binding amine: 
phosphate (N/P) ratio for PgP and siRNA. The PgP/siRNA polyplex was found to bind with 
stability at N/P ratios over 15:1 (Fig. 5), where there was no detectable unbound siRNA in the 
gel. Free siRNA suggests unstable or lack of binding with the PgP. A noticeable reduction in free 
siRNA, and therefore a noticeable increase in bound siRNA is seen starting at an N/P of 7.5. This 
finding allowed us to choose N/P ratios over 15:1 to continue forward with. In our previous 
study published in Biomaterials, we found that PgP/siRhoA at N/P 30:1 showed efficient 
knockdown in B35 cells, as well as rat spinal cord injury model in vivo89. These finding lead us to 
choose ratios, above 30:1 (30:1, 60:1 and 80:1) for further experimentation.   
Figure 5. Agarose gel shift assay of PgP complexed with siRNA. PgP binds siRNAs at various N/P ratios, with 
greatest stability found at and above N/P of 15:1 
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5.2 PgP/siMGMT polyplex characterization 
The characteristics of the PgP/siRNA polyplex were next evaluated. The particle size, 
polydispersity index and zeta potential, or polyplex surface charge, are displayed in Table 2. The 
mean polyplex particle size found using the Zetasizer ZS was about 192 nm with a PDI of 0.19. 
The polydispersity index is expected for a micellar complex such as PgP/siRNA due to the 
formulation methods. The zeta potential, a key indicator of the stability of colloidal dispersions, 
is about 48 mV, showing moderate stability (Fig. 6).  
 PgP/siRNA PgP/siRNA 
N/P Ratio 30:1 60:1 
Particle Size (nm) 201.42 ± 4.17 192.2 ± 69.23 
PDI 0.238 0.191 
Zeta Potential (mV) 30.63 ± 1.60 47.5 ±6.72 
Figure 6. Characterization of PgP/siMGMT. (A) PgP/siMGMT polyplexes were characterized for particle 
size and zeta potential using a Zetasizer NS and N/P ratios of 30:1 and 60:1. (B) The distribution of particle 
size is graphed versus intensity, displaying the average particle size around 200 nm. (C)Transmission 
electron microscope (TEM) image of PgP-complexed siRNAs at a 30:1 N/P ratio.  Gwak, S-J et al. (2016) 
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The net positive charge, from the positively charged PEI shell overcomes the siRNA’s negative 
charge at this N/P of 60:1. Positively charged particles in the body have the tendency to interact 
with negatively charged proteins, which lead us to test PgP in heparin competition and serum 
protection assays. The polyplexes were imaged previously by Gwak et al., and displayed in in 
Figure 6. They were imaged with transmission electron microscope (TEM) at 30:1 are shown to 
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5.3 PgP delivers siRNAs into glioblastoma cells in vitro  
Once the ability of PgP to bind free siRNAs was confirmed, we examined the ability of PgP to 
deliver siRNAs into cells in vitro. T98G human glioblastoma cells were incubated with FI-siNT 
alone, or complexed with PEI, lipofectamine 2000, or PgP for 6 hours.  
Qualitatively, fluorescent microscopy revealed that the PgP/FI-siNT complex produced uptake of 
the siRNA in T98G cells, shown in figure 7. Both the intensity and amount of green fluorescence 
was taken into account when visually observing transfection. When delivered alone, siRNA does 
not appear to enter the cell, or remain intact. Visually, the optimal uptake was at N/P ratio of 
60:1, but ratio 30:1 was similar. The N/P ratio of 80:1 appears to display a lower degree of 
uptake, but this is likely due to fluorescent signal quenching from the strong electrostatic 
interaction. Results were comparable to strong commercially available transfection agent 
Lipofectamine, and appeared to produce stronger signal than delivery with PEI.  
Figure 7. PgP delivers siRNAs into GBM cell in vitro. PgP at N/P ratios of 30:1, 60:1, and 80:1 mediates the 
uptake of green fluorescently labeled siRNA. Images taken my fluorescent microscopy 6 hours post-
transfection. 
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Flow cytometry was used to quantify the intracellular uptake of siRNA delivered by PgP 
6 hours post-transfection. When quantified, no significant difference was seen between each 
ratio, or the positive transfection controls of PEI and LIPO2000. Over 90% transfection efficiency 
was observed in all PgP ratios, PEI and LIPO2000, confirming the efficacy of PgP as a nucleic acid 
delivery system. This data supports the theory that the discrepancy between qualitative and 
quantitative results is due to quenching from strong positive charge of PEI in both the PEI 
positive control and the PgP 80:1. The siRNA alone showed no significant uptake compared to 
the untreated control, suggesting that the cells had almost zero transfection.   
Figure 8. PgP mediates uptake of siRNAs in human glioblastoma. T98G cells with quantitative flow cytometry 
analysis of siRNA uptake in T98G cells 6 hours post-incubation with siRNA alone, or siRNA complexed with 
polyethyleneimine (PEI) at a 5:1 N/P ratio, Lipofectamine 2000 (Lipo2000), or PgP at a 30:1, 60:1, or 80:1 N/P ratios.  
Data are mean ± SEM of three independent experiments (N=3) where ****P<0.0001 or not significant (ns) 
compared to untreated cells (one-way ANOVA).   
 
  42 
 
5.4 siRNA delivery displays minimal cytotoxicity in vitro 
Cytotoxicity of the PgP polyplexes in T98G cells was determined by the performance of MTT 
assay after transfection. Cells were treated with siNT alone or complexed with LIPO2000, or PgP 
at N/P ratios of 30:1, 60:1 and 80:1.  The results showed minimal cytotoxicity for all treatments 
in comparison to untreated cells (Fig. 9).  The percent viabilities for cells treated with PgP 
polyplexes were 85%, 90%, and 93%, at N/P ratios of 30/1, 60/1, and 80/1, respectively, 
compared to 88% viability for cells treated the lipofectamine 2000/siNT.  Overall these results 
demonstrate that PgP mediates efficient uptake of siRNAs into glioblastoma cells with minimal 
cytotoxicity, showing the potential utility of PgP as a vector for siRNA delivery. 
Figure 9. PgP polyplexes display minimal cytotoxicity in T98G cells. Quantitative analysis of T98G cell viability via 
MTT assay following 48-hour incubation with a non-targeting siRNA (siNT) alone or siNT complexed with 
Lipofectamine 2000 (Lipo2000) or PgP at a 30:1, 60:1, or 80:1 N/P ratio.  Data are mean ± SEM of three independent 
experiments (N=3) performed in triplicate where the data is not significant compared to untreated cells (one-way 
ANOVA). 
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5.5 Polyplexes enter the cell through endocytosis 
Images of T98G cells were taken to visualize uptake after transfection and staining. The 
LysoTracker™ Blue stains the acidic organelles, indicating location of endosomes.  Fluorescently 
labeled FI-siNT indicated location of the siRNA uptake within the cell. Fluorescent images of 
PgP/FI-siNT transfected cells showed colocalization of the endosomes and FI-siNT, indicating 
that the uptake of siRNA is mediated by endocytosis via endosomes. Images of the control, cells 
treated with siRNA alone, show that little green fluorescence remains after the incubation, but 
also that the clearly defined endosomes do not co-localize with the FI-siNT. Positive control 
LIPO2000 displays clear colocalization, comparable with that of PgP polyplexes. These results 
confirm the theorized method of cellular uptake of the polyplexes. 
Figure 10. PgP polyplexes enter the cell through endocytosis. Endosomes were labeled with Lysotracker blue fluorescent label, and 
siRNA was labeled with green fluorescent FI-siNT. Colocalization of endosomes and siRNA suggested the cellular uptake of the 
polyplexes was occurring at the one hour timepoint. 
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5.6 PgP mediates MGMT silencing 
After the delivery efficiency and stability of the complex was determined, analysis of the 
silencing effect of siMGMT in vitro was evaluated. The silencing of MGMT was observed on the 
mRNA and protein levels. By performing a western blot, the knockdown of MGMT on the 
protein level can be visualized, as shown in Figure 11A. Positive protein control B-Actin is used 
to visualize that comparable protein is expressed in each sample.  Comparing to non-targeting 
Figure 11. PgP polyplexes mediate silencing of MGMT in T98G cells.  (A) Western blot analysis of MGMT protein 
levels or (B) Real-time PCR analysis of MGMT mRNA levels in T98G cells 48 hours post-treatment with siMGMT 
complexed with Lipofectamine 2000 (Lipo2000) or PgP at a 30:1, 60:1, or 80:1 N/P ratio, compared to cells treated 
with Lipo2000 or PgP complexed with non-targeting siRNA (siNT) at the same N/P ratio.  β-Actin protein levels were 
monitored to ensure equal loading of samples. The MGMT mRNA levels were normalized to 18s endogenous mRNA 
levels.  Data are mean ± SEM of three independent experiments performed in triplicate, where *P<0.05, **P<0.01, 
and ****P<0.0001 (t-test) compared to cells treated with siNT-complexed PgP or Lipo2000 at the same N/P ratio. 
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controls, lighter bands are seen at N/P ratios of 30:1, 60:1 and 80:1, suggesting specificity of the 
gene silencing. Very significant reduction in expression is best visualized at N/P 80:1. At the 
mRNA level, knockdown was quantized using RT-PCR, displayed in Figure 11B. The expression 
was normalized to endogenously expressed 18s mRNA levels, and normalized to non-targeting 
controls to compare true percent expression in each sample. All N/P ratios display significant 
reduction in expression, and over 50% knockdown is seen at N/P 60:1 and 80:1. The N/P ratio of 
60:1 was chosen to move forward with in studies, because of its significant ability to silence 
MGMT, while minimizing the amount of nucleic acid used. Minimization of the total siRNA 
amount is important in preventing possible toxicities in vivo.  
5.7 PgP protects siRNA in physiological conditions 
5.7.1 Serum protection assays 
To determine the ability of the PgP to protect siRNA from degradation in relevant physiological 
conditions, polyplexes were incubated with 10% or 50% serum (FBS) for 1 hour post-
complexation. In images of polyplexes after electrophoresis, PgP shows to protect the siRNA 
after incubation in both 10% (Fig. 12A) and 50% serum (Fig. 12B), compared to when incubated 
in water. Protection is determined by the amount of siRNA that travels through the gel to the 
end compared to the negative control, siRNA alone, and positive controls PEI/siRNA and 
LIPO/siRNA, which are known to complex with and protect nucleic acids. After incubation in 
serum, the strong detergent SDS is used to dissociate the PgP from the siRNA, allowing 
remaining siRNA to run through the gel. When siRNA alone was incubated in serum conditions, 
little siRNA remains after the gel is run, compared with control siRNA incubated in water. 
 
  46 
 
Positive controls PEI/siRNA and LIPO/siRNA display maximal siRNA protection in serum and 
water, comparable to the siRNA protection seen with PgP. Streaking observed in the 10% and 
more heavily in the 50% gel is likely due to serum protein interactions or binding, where greater 
degree of binding is seen in the 50% serum than 10% serum conditions. Human blood conditions 
are comparable to 50% serum conditions, so although some protein binding was apparent, the 
A) 
B) 
Figure 12. Polyplexes protect siRNA from degradation in 10% and 50% serum conditions. A) siRNA alone or 
complexed with PgP (N/P 60:1), PEI (N/P 5:1) and LIPO were incubated in A) 10% serum  or B) 50% serum for 1 hour. 
Remaining siRNA at the bottom of the gel suggests PgP protects siRNA in 10% serum (A) and 50% serum (B).  
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high degree of siRNA protection compared to controls confirms the ability of PgP to deliver 
siRNA in vivo.  
5.7.2 RNase protection assay 
PgP/siRNA 60:1 was next complexed and incubated for 1 hour in water or 0.01µg RNase A, a 
commercially available endoribonuclease that specifically degrades single-stranded RNA at C 
and U residues. When siRNA alone was incubated in RNase, no siRNA could be seen after the gel 
was run, indicating that the RNase will completely degrade ribonucleic acids. The PgP/siRNA 
complex shows no detectable degradation after RNAse incubation, compared with the complex 





Figure 13. Polyplexes protect siRNA from degradation due to ribonucleases. siRNA alone or complexed with PgP 
(N/P 60:1), PEI (N/P 5:1) and LIPO were incubated in 0.01µg of RNase A. PgP shows to protect the siRNA from total 
degradation, as seen when siRNA alone is incubated in RNase A.  
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5.7.3 Heparin competition assay 
PgP/siRNA 60:1 polyplexes were incubated with heparin at various weight ratios (WR, Heparin: 
siRNA) to assess competitive dissociation. The polyanion heparin is a negatively charged 
polysaccharide that can compete with nucleic acids for the interactions with polycations 
present, such as the PEI shell of PgP. After incubation, gel electrophoresis was run, and samples 
were compared to a control of siRNA alone, where the free siRNA ran through the gel 
completely. At a weight ratio of 5:1, dissociation of the PgP/siRNA polyplex begins, as some 
siRNA travels through the gel. At a WR of 10:1, the siRNA almost completely travels through the 
gel, suggesting that heparin competitively interacted with the complex and bound to the PgP, 
displacing siRNA. We can conclude that at some WR between 5:1 and 10:1, the polyplex does 
not completely dissociate, and at some WR between 2:1 and 5:1 and below, the polyplex is 
completely stable. These results demonstrate the stability of the polyplex in various 
physiological conditions, allowing us to predict the stability of the polyplexes in vivo. 
Figure 14. Polyplexes remain stable in the presence of heparin up to a weight ratio (WR) of 10:1. siRNA alone or 
complexed with PgP (N/P 60:1) was incubated with heparin at various weight ratios, ranging from 0 to 100. The 
polyplex shows stability up to the WR 5:1, where dissociation begins. Total dissociation is seen at WR of 10:1.  
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5.8 Effect of MGMT knockdown on TMZ cytotoxicity  
The IC50 (half maximal inhibitory concentration), or 50% lethal dosage for TMZ in T98G cells was 
determined to be 1000µM TMZ. Once cells were treated with PgP/siMGMT or PgP/siNT, TMZ 
was added at 1000µM and 500um (half the IC50) and incubated for 72 hours. After 72 hours, an 
MTT assay was performed. Percent viability determined was normalized to untreated control. As 
displayed in Figure 15, a reduction in viability is apparent when PgP/siMGMT is used in 
combination with TMZ. After statistical analysis using one-way ANOVA, no significance was 
found between the PgP/siNT with TMZ group and the PgP/siMGMT with TMZ group. Therefore, 
a reduction in viability cannot yet be attributed to the silencing effect of siMGMT when treated 
in combination with TMZ. A reduction in cell viability is certainly apparent, but a larger sample 
size may be necessary for conclusive results.   
 
Figure 15. Combination PgP/siMGMT and temozolomide treatment reduces viability of T98G cells. Quantitative 
analysis of T98G cell viability via MTT assay 72 hours post-treatment with PgP-complexed siMGMT with or 
without concurrent temozolomide (TMZ) treatment of 500 or 1000 µM.  Untreated cells and cells treated with 
PgP complexed with a non-targeting siRNA (siNT) were used as negative controls.  Data are mean ± SEM of two 
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5.9 Xenograft glioblastoma model in mouse brain was verified 
5.9.1 H&E staining 
After injecting T98G cells into the mouse brains, the tumors were allowed to grow for 4 weeks. 
After 4 weeks, one mouse was sacrificed and the brain was harvested and preserved in 10% 
formalin for 24 hours and then 30% sucrose for 48 hours. Cryosectioning and Hematoxylin and 
Eosin (H&E) staining was performed to visualize the histological structure of the brain at the 
injection site. The slides prepared allowed us to see distinct tumor cells within the brain. As 
common with naturally occurring glioblastomas, the cells are diffuse and spread into the normal 
brain tissue, rather than forming a solid tumor mass. The cells can be identified in Figure 16, 
differentiated from normal tissue due to their fibroblastic morphology. At 2.5X, the injection site 
is easily visualized, where it has not healed fully. The sample shows that the right ventricle (side 
of injection) is significantly smaller than the left ventricle, suggesting that the GBM tissue has 
invaded the brain and is growing into the right ventricle. At 5X, the ventricle shows to have GBM 
cells within, and there is a lesion lateral and dorsal to the ventricle. At 10X, the cells can be more 
easily visualized, spreading throughout the ventricle.  
Figure 16. Glioblastoma cells visualized within mouse brain tissue ex vivo. At 2.5X magnification, the injection 
site can easily be seen, indicated by #. At 5x, a lesion is noted near the injection site, above the hippocampal 
region, indicated by *. At 10X, the fibroblastic glioblastoma cells can be seen spreading into the ventricle, 
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5.9.2 Ex vivo imaging 
After the polyplex injection and 72-hour incubation, the animals were sacrificed and brains 
removed. Brains were stored in RNAlater for 24 hours, and then placed into a mouse brain 
matrix for dissection. A slice was removed 1mm posterior and 1 mm anterior to the injection 
site (2mm total thickness). The slices were imaged with a dissection scope at 18X. The images 
showed the reduction in right ventricle size, compared to the left ventricle, for control, non-
targeting and siMGMT groups, displayed in Figure 17.  
5.10 DiR-loaded PgP/siNT remains in tumor for up to 10 days 
IVIS imaging done at 1, 3, 6 and 24 hours, 48, 72 hours and then every 48 hours up to 10 days 
showed that the DiR-loaded polyplex remained in the brain tissue for at least 10 days.  The 
minimum radiant efficiency was set to 5x106 to allow for comparison across photos. The 
polyplex could be seen in the spleen with intensity after 24 hours and sporadically throughout 
imaging. The signal in the brain seems to remain consistent with each sampling. At 10 days after 
harvesting organs, the signal could be detected in the brain, but not in any other organs as seen 
in Figure 19. This suggests that the polyplex is accumulating in the brain tissue and remains for 
Figure 17. GBM xenograft tumor model verified after sacrifice. Reduction in ventricular space indicates tumor 
growth in the right hemisphere, where injection was performed. Asterik (*) indicates the approximate cellular 
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up to 10 days without total clearance. The lack of signal in the rest of the organs suggests that 
there is no significant accumulation in peripheral organs. Clearance in the seen is expected, due 
to the nature of the positively charged polyplex, and the preference by the spleen to clear 







Figure 18. Local delivery of DiR-loaded PgP/siNT into tumor site (right mouse). Left mouse is control mouse with 
tumor but without DiR- PgP/siNT injection.  A) 1 hour post injection, B) 24 hours post injection, C) 48 days post 
injection, D) 72 days hours post injection, E) 4 days post injection, F) 6 days post injection, G) 8 days post 
injection, H) 10 days post injection. Strong DiR signal is observed at each timepoint, with little reduction in 
strength over 72 hours.   
 
Figure 19. DiR-loaded PgP/siNT remains in 
the brain tissue for at least 10 days. Organs 
harvested from control mouse (right) versus 
DiR-PgP/siNT treated mouse (left). Organs 
from top to bottom: brain, heart, lungs, 
liver, kidneys, spleen. No polyplex 
accumulation is observed in organs after 10 
days. Signal remains strong (7.4x107 radiant 
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5.11 PgP/siMGMT polyplex mediates MGMT knockdown in vivo 
Once the polyplex biodistribution was evaluated in vivo, the therapeutic effect was studied. One 
month post-xenograpft, the mice were injected with either PgP/siNT, as a non-targeting control 
or PgP/siMGMT for therapy. Control mice were not injected with therapeutic, but were injected 
initially with the GBM cells. Brain tissue was harvested 72 hours post-injection. The silencing of 
MGMT mRNA was evaluated using RT-PCR, and results are displayed in Figure 20. The group of 
Figure 20. PgP mediates knockdown of MGMT expression in vivo. Expression of MGMT on the (A) mRNA and (B) 
protein levels of brain tumor tissue harvested 72-hours post-injection of PgP/siNT or PgP/siMGMT. Values are 
normalized to MGMT expression of control group. Data are mean ± SEM, where *P<0.05. β-actin as endogenously 
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mice treated with PgP/siMGMT shows significant reduction is MGMT expression compared to 
the control group, displayed in Figure 20A. There is no significant difference between the control 
group and the mice treated with PgP/siNT, suggesting that the non-targeting control did not 
knockdown MGMT. Western blot showed that the PgP/siMGMT had knockdown at the protein 
level compared to non-targeting and untreated controls, displayed in Figure 20B. These results 
are consistent with the silencing effect seen in vitro, and provide promise that PgP is an effective 
method of gene delivery in vivo. The safety of the therapy can be commented on, in that no 
deaths or adverse effects occurred within the 72 hours after injection.   
  
 




The overall goal of this project was to use our lab’s novel delivery system, PgP, to effectively 
deliver siRNA in vitro and in vivo, to glioblastoma cells. Proving the efficacy and safety of 
siMGMT delivery would be relevant for the treatment of glioblastoma, in that it may allow for 
an increase in TMZ cytotoxicity. Increasing the toxicity would first allow for better treatment of 
the disease, eliminating more tumor cells from the body. It could further allow for lower 
dosages and therefore reduced toxic side effects, such as life-threatening myelosuppression. 
After evaluating our results, there are a few highlights and a few limitations that should be 
addressed. First, the delivery system PgP has been shown to be very effective in vitro for 
delivery of siRNA into T98G cells. It provides for over 90% transfection and over 50% gene 
knockdown. However, in vitro conditions are very different from those of the human body, 
mainly in that we see cancer cells growing in a very controlled monolayer, compared to the 
unpredictable diffuse nature of gliomas in humans, where cancerous cells spread easily into 
normal regions of the brain. The H&E staining of brain sections gave us insight into the 
development of xenograft T98G tumors in nude mice. Although no visible tumor borders were 
clear, the individual GBM cells were apparent in the injected hemisphere, traveling easily 
through the ventricle. The ex vivo slicing of the brain tissue displayed clear asymmetry between 
the right and left hemispheres.  
After DiR-PgP/siNT injections and imaging, the polyplex appears to remain stable in the brain 
tissue, and doesn’t seem to accumulate in the peripheral organs. Though, there are limitations 
to the method of local delivery, in that it may not represent the accumulation of the polyplex in 
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the tumor if it were to be administered intravenously. Local injection was also used for the 
treatment administration, which is reasonable and potentially translatable to the clinic, but 
could cause high risk of local side effects such as infection. Minimizing the number of times that 
the skull is opened for surgery is preferred to reduce contact with pathogens, especially because 
treating infection in the brain is challenging.  
After evaluating the gene silencing at the mRNA level in vivo, we can conclude that the delivery 
of siMGMT is feasible, but results had some inconsistencies. In order to determine the silencing 
effect with more accuracy, future studies should be done. Creating a tumor model using 
different cell lines may be more effective in creating solid tumors. Solid tumor tissue would 
allow for better removal of tissue and better analysis. It is likely that normal brain tissue was 
being analyzed within our tumor tissues, but in different amounts, causing variation in MGMT 
expression. Western blot displayed very light bands compared to β-actin control, suggesting that 
the MGMT levels are very low, even in control groups This may also give reason to the 
inconsistencies seen in the data after evaluating knockdown on the mRNA level. 
The combinatorial studies done, where we attempted delivering siMGMT and TMZ either 
simultaneously or in sequence, did not provide conclusive results. The study may provide insight 
into the efficacy of TMZ in general. Studies done found that it was extremely difficult to produce 
cell death, even with high concentrations of TMZ applied directly to the cells. In comparison to 
1000µM TMZ, the amount of CCNU to achieve IC50 on the T98G cells plated the same is only 
50µM.  A more effective chemotherapeutic is needed to effectively kill GBM cells. The study 
may also be limited in the methods being used. MTT assay provide a measure of metabolic 
activity of the cells after treatment. A TUNEL assay may be attempted for future studies, where 
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the apoptotic activity of the cells is quantified. Because TMZ causes double stranded DNA 
breaks, this could be an appropriate method to more accurately determine the efficacy of the 
combination treatment. Increasing sample size further could provide for more reliable results.  
Another outlook for this project would to be to effectively load an alkylating agent into the 
hydrophobic core of the PgP complex for more effective delivery of chemotherapeutics into 
glioblastoma cells. TMZ is nearly insoluble (5mg/ml) in water, so the hydrophobic core of PgP 
could potentially be an appropriate intermediate to delivery. Future work can be done with this 
to load the TMZ within the PgP and deliver the drug more effectively. Future work should 
include optimizing TMZ loading in PgP, as well as attempting to load other alkylating drugs such 
as lomustine (CCNU).  
Further additions to the delivery system could include adding a targeting moiety and additional 
siRNA conjugates. A targeting moiety can be used to actively target the tumor tissue, in addition 
to the passive targeting technique. Possible treatments to be attempted in vivo could include: 
sequential delivery of PgP/siMGMT and then delivery of targeted TMZ-loaded PgP. Optimization 
of maximum MGMT knockdown in vivo should be determined, to administer the drug loaded 
PgP when it will be most effective. Additional siRNAs could be complexed with PgP, such as to 
interfere with oncogenic, tumor promoting genes, while providing an environment for TMZ to 
work optimally. Certain angiogenic genes that could be considered for knockdown include 
vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), or platelet-
derived growth factor (PDGF). EGFR and PDGF are overexpressed in primary and secondary 
GBM, respectively, therefore could have positive effects if silenced in different GBM patients. 
VEGF is a key angiogenic factor, allowing for vessel formation and tumor proliferation in many 
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cancer types, and is already being inhibited as a treatment for GBM (bevacizumab). The co-
delivery of these siRNAs using the stable polymeric delivery system could further enhance 










In conclusion, it can be confirmed that PgP complexes with siRNAs and effectively mediates the 
delivery of siMGMT into T98G cells. It does so without significant cytotoxicity at N/P ratios of 
30:1, 60:1 and 80:1. The PgP/siMGMT polyplex allows for significant reduction in expression on 
the mRNA and protein levels in vitro, with over 50 percent knockdown at using N/P ratios of 
60:1 and 80:1. The N/P ratio of 60:1 was chosen as the ratio to move forward with in order to 
limit potential toxicity in vivo, by reducing total amount of reagent used, while still achieving 
over 50% gene silencing. Studies show that PgP protects siRNA from degradation in serum 
conditions and in the presence of ribonucleases, giving reason the believe that it will remain 
stable in the body. 
In vivo results display the ability to grow T98G glioblastoma cells in nude mice, but the ability to 
form a solid tumor is not certain. Silencing of MGMT was found to be effective in mice on the 
mRNA and protein levels, however very little MGMT expression is apparent, causing variability 
in results. While significance is seen between the MGMT knockdown and control groups, the 
significance is only one star, where P< 0.05, reflecting these variabilities. The combination of 
PgP/siMGMT and TMZ shows decreased cell viability at 500µM and 1000µM, however no 
statistical significance was found between combination therapy of PgP/siMGMT + TMZ and 
combining PgP/siNT +TMZ. This may be due to in inability of TMZ to effectively kill glioblastoma 
cells, rather than the efficacy of the PgP/siMGMT polyplex.  
Polymeric drug delivery shows great potential in the field of cancer treatment. Delivering drugs 
and genes using a multifunctional nanotherapeutic can help overcome the physical barrier of 
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the BBB, and combat chemotherapeutic resistance with gene therapy. PgP has great potential in 
becoming a new dual treatment for not only GBM, but many therapeutic areas. With further 
studies, we can hope to optimize the use of this carrier for the combinatorial delivery of 
siMGMT and TMZ, and bring longer lives to GBM patients.   
 





1. Ostrom, Q. T. et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in 
the United States in 2006 - 2010. J. Neurooncol. 15, 788–796 (2013). 
2. Alifieris, C. & Trafalis, D. T. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol. Ther. 152, 63–
82 (2015). 
3. Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta 
Neuropathologica 114, 97–109 (2007). 
4. Jhanwar-Uniyal, M., Labagnara, M., Friedman, M., Kwasnicki, A. & Murali, R. Glioblastoma: Molecular 
pathways, stem cells and therapeutic targets. Cancers (Basel). 7, 538–555 (2015). 
5. Holland, E. C. Glioblastoma multiforme: the terminator. Proc. Natl. Acad. Sci. U. S. A. 97, 6242–6244 (2000). 
6. Stupp, R., Hegi, M. E. & Mason, W. P. Effects of radiotherapy with concomitant and adjuvant temozolomide 
versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the 
EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009). 
7. Hottinger, A. F., Stupp, R. & Homicsko, K. Standards of care and novel approaches in the management of 
glioblastoma multiforme. Chin. J. Cancer 33, 32–39 (2014). 
8. Bota, D. A., Desjardins, A., Quinn, J. A., Affronti, M. L. & Friedman, H. S. Interstitial chemotherapy with 
biodegradable BCNU (Gliadel?? ) wafers in the treatment of malignant gliomas. Ther. Clin. Risk Manag. 3, 
707–715 (2007). 
9. Chowdhary, S. A., Ryken, T. & Newton, H. B. Survival outcomes and safety of carmustine wafers in the 
treatment of high-grade gliomas: a meta-analysis. J. Neurooncol. 122, 367–382 (2015). 
10. Cohen, M. H., Shen, Y. L., Keegan, P. & Pazdur, R. FDA drug approval summary: Bevacizumab (Avastin) as 
treatment of recurrent glioblastoma multiforme. Oncologist 14, 1131–1138 (2009). 
11. Van Tellingen, O. et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug 
Resist. Updat. 19, 1–12 (2015). 
12. Rong, Y. et al. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in 
glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res. 66, 
7067–7074 (2006). 
13. Kleihues, P. & Ohgaki, H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro. 
Oncol. 1, 44–51 (1999). 
14. Wrensch, M., Minn, Y., Chew, T., Bondy, M. & Berger, M. S. Epidemiology of primary brain tumors: current 
concepts and review of the literature. Neuro Oncol 4, 278–299 (2002). 
15. Burch, J. D. et al. An exploratory case-control study of brain tumors in adults. J. Natl. Cancer Inst. 78, 601–
609 (1987). 
16. Zahm, S. H. & Ward, M. H. Pesticides and childhood cancer. in Environmental Health Perspectives 106, 893–
908 (1998). 
17. Vogelstein, B. & Kinzler, K. W. The multistep nature of cancer. Trends in Genetics 9, 138–141 (1993). 
18. Verhaak, R., Hoadley, K., Purdon, E. & Getz, G. An integrated genomic analysis identifies clinically relevant 
subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 19, 38–
 
  62 
 
46 (2010). 
19. Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes and Development 18, 1926–1945 
(2004). 
20. Louis, D. N. Molecular Pathology of Malignant Gliomas. Annu. Rev. Pathol. Mech. Dis. 1, 97–117 (2006). 
21. Gomez-Manzano, C. et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized 
death of human glioma cells via apoptosis. Cancer Res. 56, 694–699 (1996). 
22. Yoshino, A. et al. Effect of IFN-beta on human glioma cell lines with temozolomide resistance. Int. J. Oncol. 
151, 414–420 (2009). 
23. Stupp, R. et al. Radiotherapy plus Concomitant\nand Adjuvant Temozolomide for Glioblastoma. N. Engl. J. 
Med. 987–96 (2005). doi:10.1056/NEJMoa043330 
24. Mrugala, M. M. & Chamberlain, M. C. Mechanisms of Disease: temozolomide and glioblastoma—look to the 
future. Nat. Clin. Pract. Oncol. 5, 476–486 (2008). 
25. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 
997–1003 (2005). 
26. Westphal, M. et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers 
(Gliadel wafers) in patients with primary malignant glioma. Neuro. Oncol. 5, 79–88 (2003). 
27. Wait, S. D., Prabhu, R. S., Burri, S. H., Atkins, T. G. & Asher, A. L. Polymeric drug delivery for the treatment of 
glioblastoma. Neuro. Oncol. 17, ii9-ii23 (2015). 
28. Zhou, J. et al. Highly penetrative , drug-loaded nanocarriers improve treatment of glioblastoma. (2013). 
doi:10.1073/pnas.1304504110 
29. Maxwell, M. et al. Expression of angiogenic growth factor genes in primary human astrocytomas may 
contribute to their growth and progression. Cancer Res. 51, 1345–51 (1991). 
30. Kreisl, T. N. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor 
progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740–745 (2009). 
31. Banks, W. A. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 9, S3 (2009). 
32. Horio, M., Gottesman, M. M. & Pastan, I. ATP-dependent transport of vinblastine in vesicles from human 
multidrug-resistant cells. Proc Natl Acad Sci U S A 85, 3580–4 (1988). 
33. Schinkel, A. H., Wagenaar, E., Mol, C. A. A. M. & Van Deemter, L. P-glycoprotein in the blood-brain barrier of 
mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97, 2517–
2524 (1996). 
34. Choo, E. F. et al. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, 
and the blood-brain barrier. J. Pharmacol. Exp. Ther. 317, 1012–1018 (2006). 
35. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751–760 
(2007). 
36. Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F. & Farokhzad, O. C. Targeted polymeric 
therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 41, 2971–3010 (2012). 
37. Kim, S. S., Harford, J. B., Pirollo, K. F. & Chang, E. H. Effective treatment of glioblastoma requires crossing the 
blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine. 
Biochemical and Biophysical Research Communications 468, 485–489 (2015). 
38. Hardee, M. E. & Zagzag, D. Mechanisms of glioma-associated neovascularization. American Journal of 
Pathology 181, 1126–1141 (2012). 
 
  63 
 
39. S??h??dic, D., Cikankowitz, A., Hindr??, F., Davodeau, F. & Garcion, E. Nanomedicine to overcome 
radioresistance in glioblastoma stem-like cells and surviving clones. Trends Pharmacol. Sci. 36, 236–252 
(2015). 
40. Hegi, M. & Diserens, A. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. 
Med. 352, 997–1003 (2005). 
41. Zhang, J., Stevens, M. F. G. & Bradshaw, T. D. Temozolomide: Mechanisms of Action, Repair and Resistance. 
Curr. Mol. Pharmacol. 5, 102–114 (2012). 
42. Tolcher, A. W. et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted 
temozolomide schedules. Br. J. Cancer 88, 1004–1011 (2003). 
43. Munoz, J. L. et al. Temozolomide Induces the Production of Epidermal Growth Factor to Regulate MDR1 
Expression in Glioblastoma Cells. Mol. Cancer Ther. 13, 2399–2411 (2014). 
44. Donson, A. M., Addo-Yobo, S. O., Handler, M. H. M., Gore, L. M. & Foreman, N. K. MGMT Promoter 
Methylation Correlates With Survival Benefit and Sensitivity to Temozolomide in Pediatric Glioblastoma. J. 
Clin. Oncol. 14, 1526–1531 (1996). 
45. Warren, K. E. et al. A Phase II Study of O6-Benzylguanine and Temozolomide in Pediatric Patients with 
Recurrent or Progressive High Grade Gliomas and Brainstem Gliomas: A Pediatric Brain Tumor Consortium. J 
Neurooncol 106, 643–649 (2012). 
46. Kato, T. et al. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of 
temozolomide in GBM-initiating cells. Gene Ther. 17, 1363–1371 (2010). 
47. de Faria, G. P. & de Oliveria, J. A. Differences in the Expression Pattern of P-Glycoprotein and MRP1 in Low-
Grade and High-Grade Gliomas. Cancer Invest. 26, 883–889 (2008). 
48. Beier, D., Schulz, J. B. & Beier, C. P. Chemoresistance of glioblastoma cancer stem cells - much more complex 
than expected. Mol. Cancer 10, 128 (2011). 
49. Van Den Bent, M. J. et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in 
recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27, 1268–1274 (2009). 
50. Hegi, M. E. et al. Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR 
Tyrosine Kinase Inhibitor Gefitinib--A Phase II Trial. Mol. Cancer Ther. 10, 1102–1112 (2011). 
51. Neyns, B. et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann. Oncol. 
20, 1596–1603 (2009). 
52. Wang, K., Park, J. O. & Zhang, M. Treatment of glioblastoma multiforme using combination of siRNA targeting 
EGFR and β-catenin. J. Gene Med. 15, 42–50 (2013). 
53. Den, R. B. et al. A phase i study of the combination of sorafenib with temozolomide and radiation therapy for 
the treatment of primary and recurrent high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. 85, 321–328 
(2013). 
54. Lee, E. Q. et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or 
gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro. Oncol. 14, 1511–1518 (2012). 
55. Reardon, D. A. et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II 
study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J. Neurooncol. 101, 57–66 
(2011). 
56. Sonabend, A. M., Ulasov, I. V & Lesniak, M. S. Gene therapy trials for the treatment of high-grade gliomas. 
Gene Ther. Mol. Biol. 11, 79–92 (2007). 
57. Oldfield, E. H. et al. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with 
 
  64 
 
the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39–69 (1993). 
58. Braun, E. Neurotropism of herpes simplex virus type 1 in brain organ cultures. J. Gen. Virol. 87, 2827–2837 
(2006). 
59. Peltékian, E., Garcia, L. & Danos, O. Neurotropism and Retrograde Axonal Transport of a Canine Adenoviral 
Vector: A Tool for Targeting Key Structures Undergoing Neurodegenerative Processes. Mol. Ther. 5, 25–32 
(2002). 
60. Kim, S. H., Xiao, S., Shive, H., Collins, P. L. & Samal, S. K. Replication, neurotropism, and pathogenicity of avian 
paramyxovirus serotypes 1-9 in chickens and ducks. PLoS One 7, (2012). 
61. Okura, H., Smith, C. A. & Rutka, J. T. Gene therapy for malignant glioma. Mol. Cell. Ther. 2, 21 (2014). 
62. Rainov, N. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene 
therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma 
multiforme. Hum. Gene Ther. 11, 2389–401 (2000). 
63. Aguilar, L. K. et al. Phase II multicenter study of gene mediated cytotoxic immunotherapy as adjuvant to 
surgical resection for newly diagnosed malignant glioma. J Clin Oncol (Meeting Abstr. 33, 2010 (2015). 
64. Kalkanis, S. et al. Intravenous Administration of Toca 511 in Patients With Recurrent Glioblastoma. Neuro. 
Oncol. 16, v15–v15 (2014). 
65. Zhang, J. & Saltzman, M. Engineering biodegradable nanoparticles for drug and gene delivery. Chem. Eng. 
Prog. 109, 25–30 (2013). 
66. Waite, C. L. & Roth, C. M. PAMAM-RGD Conjugates Enhance siRNA Delivery Through a Multicellular Spheroid 
Model of Malignant Glioma. Bioconjug Chem 20, 1908–1916 (2011). 
67. Wang, S. et al. The role of autophagy in the neurotoxicity of cationic PAMAM dendrimers. Biomaterials 35, 
7588–7597 (2014). 
68. Mangraviti, A. et al. Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. 
ACS Nano 9, 1236–1249 (2015). 
69. Guerrero-Cázares, H. et al. Biodegradable Polymeric Nanoparticles Show High Efficacy and Specificity at DNA 
Delivery to Human Glioblastoma in Vitro and in Vivo. ACS Nano 8, 5141–5153 (2014). 
70. Zhan, C. et al. Cyclic RGD-polyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene 
delivery. Chem. - An Asian J. 7, 91–96 (2012). 
71. de Lima, M. C. et al. Gene delivery mediated by cationic liposomes: from biophysical aspects to enhancement 
of transfection. Mol Membr Biol 16, 103–109 (1999). 
72. Balazs, D. A. & Godbey, W. Liposomes for Use in Gene Delivery. J. Drug Deliv. 2011, 1–12 (2011). 
73. Lin, Q. et al. Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded 
cationic liposomes. Cancer Chemother. Pharmacol. 77, 269–280 (2016). 
74. Calcagno, C., Lobatto, M. E., Robson, P. M. & Millon, A. Encapsulation of temozolomide in a tumor-targeting 
nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Cancer 
Lett. 28, 1304–1314 (2015). 
75. Qu, J. et al. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of 
drug delivery system is better for glioblastoma chemotherapy? Drug Deliv. 23, 3408–3416 (2016). 
76. Chen, Z., Lai, X., Song, S., Zhu, X. & Zhu, J. Nanostructured lipid carriers based temozolomide and gene co-
encapsulated nanomedicine for gliomatosis cerebri combination therapy. Drug Deliv. 23, 1369–73 (2016). 
77. Guo, W., Chen, W., Yu, W., Huang, W. & Deng, W. Small interfering RNA-based molecular therapy of cancers. 
 
  65 
 
Chin. J. Cancer 32, 488–493 (2013). 
78. Mansoori, B., Shotorbani, S. S. & Baradaran, B. RNA interference and its role in cancer therapy. Adv. Pharm. 
Bull. 4, 313–321 (2014). 
79. Yoo, B., Ifediba, M. A., Ghosh, S., Medarova, Z. & Moore, A. Combination treatment with theranostic 
nanoparticles for glioblastoma sensitization to TMZ. Mol. Imaging Biol. 16, 680–689 (2014). 
80. Kanasty, R., Dorkin, J. R., Vegas, A. & Anderson, D. Delivery materials for siRNA therapeutics. Nat Mater 12, 
967–977 (2013). 
81. Jones, S. K. & Merkel, O. M. Tackling breast cancer chemoresistance with nano-formulated siRNA. Gene Ther. 
23, 821–828 (2016). 
82. Fenstermaker, R. A. et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with 
recurrent malignant glioma. Cancer Immunol. Immunother. 65, 1339–1352 (2016). 
83. Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S. & Ganne, V. Montanide ISA 720 and 51: a new generation 
of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1, 111–118 (2002). 
84. Liu, Y., Miao, C., Wang, Z., He, X. & Shen, W. Survivin small interfering RNA suppresses glioblastoma growth 
by inducing cellular apoptosis. Neural Regen. Res. 7, 924–931 (2012). 
85. Portnow, J. et al. Neural Stem Cell–Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent 
High-Grade Glioma Patients. Clin. Cancer Res. (2016). doi:10.1158/1078-0432.CCR-16-1518 
86. Kim, S.-S., Rait, A., Kim, E., Pirollo, K. F. & Chang, E. H. A Tumor-targeting p53 Nanodelivery System Limits 
Chemoresistance to Temozolomide Prolonging Survival in a Mouse Model of Glioblastoma Multiforme Sang-
Soo. J. Nanomedicine 11, 301–311 (2015). 
87. Quinn, J. A. et al. Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults with Recurrent, 
Temozolomide-Resistant Malignant Glioma. J. Clin. Oncol. 27, 1262–1267 (2009). 
88. Pirollo, K. F. et al. Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 
Gene Used in Combination with Docetaxel: A Phase 1b Study. Mol. Ther. 24, 1697–1706 (2017). 
89. Gwak, S.-J. et al. Cationic, amphiphilic copolymer micelles as nucleic acid carriers for enhanced transfection 
in rat spinal cord. Acta Biomater. 18, 1067–1073 (2015). 
 
